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Abstract 
Introduction 
We present international consensus recommendations for improving diagnosis, management and 
treatment access in multiple sclerosis (MS). Our vision is that these will be used widely among those 
committed to creating a better future for people with MS and their families. 
Methods 
Structured discussions and literature searches conducted in 2015 examined the personal and 
economic impact of MS, current practice in diagnosis, treatment and management, definitions of 
disease activity and barriers to accessing disease-modifying therapies (DMTs). 
Results 
Delays often occur before a person with symptoms suggestive of MS sees a neurologist. Campaigns 
to raise awareness of MS are needed, as are initiatives to improve access to MS healthcare 
professionals and services. 
We recommend a clear treatment goal: to maximize neurological reserve, cognitive function and 
physical function by reducing disease activity. Treatment should start early, with DMT and lifestyle 
measures. All parameters that predict relapses and disability progression should be included in the 
definition of disease activity and monitored regularly when practical. On suboptimal control of disease 
activity, switching to a DMT with a different mechanism of action should be considered. A shared 
decision-making process that embodies dialogue and considers all appropriate DMTs should be 
implemented.  Monitoring data should be recorded formally in registries to generate real-world 
evidence. 
In many jurisdictions, access to DMTs is limited. To improve treatment access the relevant bodies 
should consider all costs to all parties when conducting economic evaluations and encourage the 
continuing investigation, development and use of cost-effective therapeutic strategies and alternative 
financing models. 
Conclusions 
The consensus findings of an international author group recommend a therapeutic strategy based on 
proactive monitoring and shared decision-making in MS. Early diagnosis and improved treatment 
access are also key components. 
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Abbreviations 
AAN American Academy of Neurology 
ABN Association of British Neurologists 
AUD Australian dollars 
CIS clinically isolated syndrome 
CNS central nervous system 
DMT disease-modifying therapy 
EDSS Kurtzke Expanded Disability Status Scale 
EMA European Medicines Agency (the European regulatory authority) 
EUReMS European Register for Multiple Sclerosis 
FDA Food and Drug Administration (the US regulatory authority) 
GP general practitoner (family or primary care physician) 
HTA health technology assessment 
MoA mechanism of action 
MRI magnetic resonance imaging 
MS multiple sclerosis 
NEDA no evidence of disease activity 
NRSPMS non-relapsing secondary progressive multiple sclerosis 
PPMS primary progressive multiple sclerosis 
QALY quality-adjusted life year 
RICT randomized controlled trial 
RIS radiologically isolated syndrome 
RRMS relapsing–remitting multiple sclerosis 
RSPMS relapsing secondary progressive multiple sclerosis 
RWE real-world evidence 
SPMS secondary progressive multiple sclerosis 
US$ US dollars 
€ euros 
In this report, the term established DMTs refers to disease-modifying therapies approved for 
relapsing forms of MS during the 1990s, and to reformulations and generic versions of these 
substances.  
In this report, the term newer DMTs refers to disease-modifying therapies approved for relapsing 
forms of MS after the 1990s that have different mechanisms of action from established DMTs; some 
newer DMTs have an evidence base supporting efficacy superior to that of an established DMT, 
which may include head-to-head clinical trials or real-world evidence. 
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Graphical abstract 
 
Keywords 
multiple sclerosis 
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Highlights 
 Consensus recommendations on MS diagnosis, management and treatment are presented. 
 Neurological reserve, a component of brain health, can compensate for CNS damage. 
 We propose a therapeutic strategy that aims to maximize lifelong brain health. 
 Proactive monitoring, shared decision-making and improved treatment access are key. 
 Early referral, diagnosis and treatment initiation are also of crucial importance. 
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Preface 
This report presents an expert, evidence-based position for policy recommendations aimed at 
improving outcomes for people with multiple sclerosis (MS). It summarizes the evidence and 
consensus findings from the structured discussions of a global author group, comprising clinicians, 
researchers, specialist nurses, health economists and representatives from patient groups, all with 
expertise and experience in the area of MS.  
In summarizing the available data, this report: 
 demonstrates the personal and economic impact of MS (Section 1) 
 examines the reasons behind delays in diagnosis (Section 2) 
 presents the evidence base for a therapeutic strategy that aims to maximize lifelong brain 
health, centred around a more urgent approach to management, which involves: 
 early intervention with therapies most likely to provide optimal benefit and safety for each 
person with MS on an individualized basis (Section 3) 
 regular monitoring of disease activity and safety parameters (Section 4) 
 switching therapy based on evidence of disease activity (Section 5) 
 provides guidance on how to improve access to treatment in order to create the optimal 
environment for this therapeutic strategy (Section 6). 
Our vision is that the report and its recommendations will be used widely among those committed to 
creating a better future for people with MS and their families. Healthcare professionals, patient 
groups, healthcare authorities, health technology assessors, insurance companies, payers, regulatory 
authorities, government bodies, pharmaceutical companies and other relevant stakeholders who 
influence care quality can affect these outcomes; all have a responsibility to strive towards the highest 
possible standards of care. 
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Executive summary 
Multiple sclerosis (MS) is an incurable chronic disease in which the body’s own immune 
system destroys tissue in the brain and spinal cord. It is the leading cause of non-traumatic 
disability among young and middle-aged adults in many developed countries, and it affects 2.3 million 
people worldwide (Multiple Sclerosis International Federation, 2013a). Although there is no cure for 
MS, therapies exist that can alter the disease course by reducing disease activity and slowing down 
the accumulation of disability. This report recommends specific actions that aim to achieve the best 
possible outcome for every person with MS (Appendix A). 
A therapeutic strategy that offers the best chance of preserving brain and spinal cord tissue 
early in the disease course needs to be widely accepted – and urgently adopted (Figure A.1). 
Even in the early stages of MS, cognition, emotional well-being, quality of life, day-to-day activities 
and ability to work can be markedly affected by the damage occurring in the brain and spinal cord. As 
the disease progresses, increasing disability – such as difficulties in walking – imposes a heavy 
burden on people with MS and on their families. It also leads to substantial economic losses for 
society, owing to diminished working capacity. 
Significant delays often occur before a person with symptoms suggestive of MS sees a 
neurologist for diagnosis and treatment. This is despite diagnosis being 10 times more rapid now 
than in the 1980s (Marrie et al., 2005) and substantial evidence that early treatment is more effective 
than later treatment. Campaigns to raise awareness of MS among the general public and among 
clinicians who make referrals are urgently needed, as they have the potential to improve outcomes by 
enabling earlier diagnosis. Initiatives to improve access to specialist MS healthcare professionals and 
specialized diagnostic procedures are also needed.  
Early intervention is vital. Appropriate lifestyle interventions, treatment with a therapy that can 
reduce disease activity and consideration of rapid switching to another therapy if monitoring reveals a 
suboptimal response are crucial elements of the strategy. Involving people with MS proactively in 
decision-making and in managing their disease is also key to the successful management of MS. 
Healthcare professionals should encourage those in their care to play a fully informed, shared role in 
treatment decisions and to live a ‘brain-healthy’ lifestyle. 
Regular monitoring of disease activity and recording this information formally are the 
cornerstone of the strategy recommended by the authors. The results of clinical examinations 
and brain scans will enable personalized treatment for every person with MS and will generate long-
term real-world evidence that can be used by regulatory bodies, health technology assessors, payers 
and clinicians for evaluating therapeutic strategies.  
Offering the full range of therapies that can reduce disease activity improves the chance of 
finding the best option for each person with MS. The number of effective therapies continues to 
grow, providing increasing scope to tailor treatment to individual needs. In many jurisdictions, 
however, access to therapies is limited by licensing stipulations, prescribing guidelines or 
reimbursement decisions; these typically lag behind the most recent clinical trial data and real-world 
evidence. We therefore call on regulatory bodies, healthcare authorities, insurance companies, health 
technology assessors and payers to improve access to therapies, so that personalized treatment can 
be optimized. We also recommend that the relevant bodies consider all costs to all parties when 
conducting economic evaluations and that they encourage the continuing investigation, development 
and use of cost-effective therapeutic strategies and alternative financing models. 
Major public policy changes are needed in order to translate recent advances in the diagnosis 
and treatment of MS into improved outcomes. Enabling and promoting widespread adoption of the 
therapeutic strategy for MS recommended in this report has the potential to minimize disease activity 
This is an author’s draft of an accepted article submitted and 
published in Multiple Sclerosis and Related Disorders 
DOI: http://www.sciencedirect.com/science/article/pii/S221103481630102X 
 
 
8 
 
and maximize lifelong brain health for those with the disease. It is time to make a real difference to the 
lives of people with MS and their families – and to avoid many of the long-term economic and 
personal costs that result from unnecessary irreversible disability. 
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Endorsements 
The organizations listed below endorse the recommendations made in this report. 
 Accelerated Cure Project for Multiple Sclerosis 
 ACTRIMS (Americas Committee for Treatment and Research in Multiple Sclerosis) 
 BCTRIMS (Brazilian Committee for Treatment and Research in Multiple Sclerosis) 
 Consortium of Multiple Sclerosis Centers 
 Czech MS Society (Unie ROSKA) 
 ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) 
 European Brain Council 
 European Multiple Sclerosis Platform 
 International Organization of Multiple Sclerosis Nurses 
 International Society of Neuroimmunology 
 LACTRIMS (Latin-American Committee for Treatment and Research in Multiple Sclerosis) 
 MENACTRIMS (Middle East North Africa Committee for Treatment and Research in 
Multiple Sclerosis) 
 MexCTRIMS (Mexican Committee for Treatment and Research in Multiple Sclerosis) 
 Multiple Sclerosis Australia 
 Multiple Sclerosis International Federation 
 Multiple Sclerosis Ireland 
 Multiple Sclerosis Research Australia 
 Multiple Sclerosis Society 
 Multiple Sclerosis Society of Canada 
 Multiple Sclerosis Society of Norway (Multippel Sklerose Forbundet) 
 Multiple Sclerosis Trust 
 National Multiple Sclerosis Society 
 PACTRIMS (Pan-Asian Committee for Treatment and Research in Multiple Sclerosis) 
 RUCTRIMS (Russian Committee for Treatment and Research in Multiple Sclerosis) 
 SFSEP (Société Francophone de la Sclérose en Plaques) 
 Shift.ms 
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1. Raise awareness of the global burden of multiple sclerosis 
Key points 
 In multiple sclerosis (MS), tissue in the brain, spinal cord and optic nerve is destroyed by 
the body’s own immune system, often leading to physical disability and cognitive 
impairment. 
 MS typically affects young adults in the prime of life. For many, bouts of symptoms 
(relapses), disability progression, fatigue and cognitive impairment markedly reduce their 
quality of life and ability to work or study. 
 As disability worsens, personal and economic costs soar. Most of this additional burden 
falls on people with MS and on family members, many of whom become lifelong caregivers. 
 Early and appropriate treatment can markedly reduce disease activity and accumulation of 
disability, but there is currently no cure for MS. 
1.1 Multiple sclerosis affects young adults worldwide 
MS is a progressive neurodegenerative disease that typically affects young adults in the prime of life, 
causing irreversible physical and mental disability. It is the leading cause of non-traumatic disability 
among young and middle-aged people in many developed countries (Multiple Sclerosis International 
Federation, 2013a). MS is the most common cause of wheelchair use among those aged 18–64 years 
(Kaye et al., 2000), and the third most common cause of paralysis (after stroke and spinal cord injury) 
across all age groups (Cahill et al., 2009) in the USA. The disease thus negatively affects the lives of 
people with MS and their families, and leads to large, long-term health and economic burdens. 
Globally, the estimated number of people with MS has increased from 2.1 million in 2008 (World 
Health Organization, 2008) to 2.3 million in 2013 (Multiple Sclerosis International Federation, 2013a). 
Better reporting and diagnosis (Multiple Sclerosis International Federation, 2013a) and improved 
survival (Marrie et al., 2010b) may have contributed to this change, although the disease has been 
shown to be on the increase in a UK population (Hirst et al., 2009). MS is found worldwide but it 
becomes more common with increasing distance from the equator, particularly in the northern 
hemisphere (Simpson et al., 2011). It is most prevalent in North America, Europe, Australia, New 
Zealand (Multiple Sclerosis International Federation, 2013a), other countries with Caucasian 
populations (Multiple Sclerosis International Federation, 2013i) and Iran (Etemadifar et al., 2013). The 
causes of MS are unclear, but risk is partially determined by a complex interaction between genetic 
(Robertson et al., 1996; Carton et al., 1997; Willer et al., 2003; De Jager et al., 2009) and 
environmental (Martyn et al., 1993; Levin et al., 2005; Handunnetthi et al., 2010; Levin et al., 2010; 
Solomon and Whitham, 2010; Handel et al., 2011; Simpson et al., 2011; Torkildsen et al., 2012; 
Disanto et al., 2013; Berg-Hansen et al., 2014; Breuer et al., 2014; Fiddes et al., 2014; Spelman et al., 
2014; Torkildsen et al., 2014; Marsh-Wakefield and Byrne, 2015) factors. 
Typically, MS is diagnosed in young, active people in their 20s or 30s (Compston and Coles, 2002), 
and about two-thirds of those affected are women (Multiple Sclerosis International Federation, 
2013a). MS therefore affects people with the potential for many decades of employment ahead of 
them, who also may be making decisions about starting and raising families. 
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1.2 Multiple sclerosis is progressive and irreversible 
1.2.1 Brain tissue is damaged and brain volume is lost 
In MS, the immune system mistakenly attacks and damages tissue in the brain, spinal cord and optic 
nerve, collectively known as the central nervous system (CNS). This results in lesions (areas of acute 
injury) that can be seen in a brain scan or post-mortem examination, as well as diffuse damage that is 
more difficult to observe (Filippi and Rocca, 2005). Although repair mechanisms operate in the CNS, 
repair is often incomplete, some nerve tissue is irreversibly destroyed and the brain begins to atrophy 
(decrease in volume) more rapidly than in people unaffected by MS (Trapp et al., 1999; De Stefano et 
al., 2001; Kuhlmann et al., 2002; Schirmer et al., 2009; De Stefano et al., 2010; Sbardella et al., 
2013). 
In healthy adults, a small amount of brain atrophy occurs with ageing – in the region of 0.1–0.5% per 
year (De Stefano et al., 2016). However, in many people with untreated MS the brain typically 
atrophies at a much higher rate, at about 0.5–1.35% per year (Figure 1) (De Stefano et al., 2014a; De 
Stefano et al., 2016). Accelerated brain atrophy starts early, often before a diagnosis of MS (Figure 
2a), and proceeds throughout the course of the disease if left untreated (De Stefano et al., 2010). The 
goal of treating MS should be to prevent damage to the brain and spinal cord that leads to 
accelerated atrophy. 
1.2.2 Symptom burden worsens as damage to the brain accumulates 
The brain appears to have an inbuilt neurological reserve – a finite capacity to retain function by 
remodelling itself to compensate for loss of nerve cells, loss of nerve fibres and atrophy. It does this 
partly by rerouting signals via undamaged areas or adapting undamaged areas to take on new 
functions (Rocca et al., 2003; Rocca and Filippi, 2007). This ability is present in addition to the 
mechanisms that exist to repair physical damage to the CNS. Neurological reserve and repair 
mechanisms explain why MS-related brain damage may go undetected during the early phase of the 
disease – and therefore why MS may be undiagnosed and untreated for a long time. There is 
evidence that cognitive impairment is present in a significant proportion of people before the clinical 
symptoms of MS appear – sometimes years before (Sinay et al., 2015). It is therefore important to 
diagnose MS as early as possible (Section 2), before neurological reserve is exhausted and the 
progressive stage of the disease begins (Figure 2b). 
Usually, damage to the CNS is first detected when clinical symptoms appear. Symptoms may take the 
form of an attack (known as a relapse, or bout), when a lesion develops in a location that noticeably 
disrupts nerve function, although most lesions (~90%) do not directly lead to relapses (Figure 2c, 2d) 
(Barkhof et al., 1992; Kappos et al., 1999). Clinically evident progression of symptoms can also occur 
from the onset if neurological reserve is exhausted before a relapse occurs; however, progressive 
disease most often manifests after a period of relapses and remissions. Occasionally, lesions are 
detected before any clinical symptoms appear, on a brain scan (Okuda et al., 2009) that is conducted 
for another purpose (for example, headaches). 
The range of symptoms experienced by a person with MS (Figure 3) (Compston and Coles, 2008; 
Giovannoni et al., 2012) can depend on the locations of lesions in the CNS. The most common clinical 
symptoms reported when first visiting a healthcare professional are sensory (40% of people with MS; 
numbness, tingling, burning pain), motor (39% of people with MS; weakness, stiffness, clumsiness, 
difficulty with walking), visual (30%) and fatigue (30%; a feeling of lacking physical or mental energy 
that interferes with usual or desired activities) (Multiple Sclerosis International Federation, 2013a). 
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First-person account (Mayo Clinic, 2010) 
The fine motor coordination in my left hand was affected, at times my speech was slurred, and the 
stiffness in my legs made walking extremely tiring and difficult ... . I had gone from a very healthy and 
physically active person to a very handicapped one. My whole life had changed. 
With permission from Mayo Clinic 
 
First-person account (Borreani et al., 2014) 
I always need help ... . That really kills me. I’ve stopped going out because I’m afraid of doing it in my 
pants ... . I’m always scared of sudden incontinence and creating a stink. 
1.2.3 Multiple sclerosis typically involves relapses and progression 
People with brain lesions who have not yet had any clinical symptoms are said to have radiologically 
isolated syndrome (RIS) (Figure 2d, 2e). About one-third of people with RIS will go on to experience 
at least one attack of clinical symptoms within 5 years (Okuda et al., 2014). An initial attack of 
symptoms is known as a clinically isolated syndrome (CIS) (Figure 2d, 2e) (Miller et al., 2005). Many 
people (approximately 30–70%) with CIS will develop MS, even though they may not initially meet the 
full diagnostic criteria for the disease (Miller et al., 2005). 
About 80–90% of people with MS will initially have the relapsing–remitting form of the disease 
(RRMS) (Figure 2d, 2e) (Compston and Coles, 2008; Koch et al., 2010). People with RRMS 
experience acute (sudden) attacks of symptoms (relapses). Usually, a relapse develops over a few 
days, before the symptoms plateau and ease off (remit) over the following few weeks or months 
(Leary et al., 2005); during this time CNS repair mechanisms operate and neurological reserve is 
‘used up’ to remodel and compensate for the damage (Rocca et al., 2003; Rocca and Filippi, 2007). 
Although complete physical recovery from a relapse often occurs (most likely early on) (Berkovich, 
2013), relapses can also be associated with a sustained increase in disability (Lublin et al., 2003; 
Cutter et al., 2013). Incomplete recovery from relapses contributes to stepwise disability progression 
(Leary et al., 2005; Berkovich, 2013). 
If and when neurological reserve and repair mechanisms are exhausted, and can no longer 
compensate for damage, a stage of progressive disability begins, called secondary progressive MS 
(SPMS) (Schwartz et al., 2013). In SPMS, disability progressively worsens (with or without relapses) 
(Compston and Coles, 2008; Weiner, 2009; Lublin et al., 2014), especially the ability to walk 
(Confavreux et al., 2000). Typically, there is an ‘overlap’ phase during which relapses still occur 
(relapsing SPMS, RSPMS), followed by progression with no relapses (non-relapsing SPMS, 
NRSPMS) (Figure 2d, 2e). If RRMS is left untreated, 50–60% of people develop SPMS within 15–20 
years and it takes only 14 years on average for people to become unable to walk for 100 metres 
unaided (Scalfari et al., 2014). In addition, about 10–15% of people with MS have a progressive 
disease course from the outset, with a gradual progression of clinical symptoms in the absence of 
relapses (known as primary progressive MS; PPMS) (Miller and Leary, 2007). 
1.2.4 Appropriate drug treatment can reduce disease activity 
The key therapeutic strategy in MS should be to minimize relapses, lesions and brain atrophy at all 
stages of the disease. This is especially important in early disease, when it is possible to reduce the 
number of new lesions and amount of brain inflammation, both of which lead to atrophy. This 
approach aims to maximize brain health, productivity and quality of life. 
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A number of disease-modifying therapies (DMTs) have been approved in various jurisdictions for 
treating CIS and relapsing forms of MS. These drugs can directly affect the disease course by 
reducing relapses, slowing disability progression, reducing the number of new lesions and slowing the 
rate of brain atrophy (Sections 3–5). To date, no DMTs have been approved for PPMS, and the only 
DMT to have been approved in a small number of jurisdictions for NRSPMS has since been removed 
from the market in the USA. Relapsing forms of MS are therefore the main focus of the DMT-related 
sections of this report. 
1.3 Multiple sclerosis affects all areas of life 
1.3.1 Quality of life decreases as the disease advances 
Disability in MS is typically measured using the Kurtzke Expanded Disability Status Scale (EDSS), 
which allocates increasing numerical values to greater levels of physical disability (0.0, normal 
neurological functioning; 10.0, death) (Kurtzke, 1983). However many factors that affect quality of life, 
such as mental health, vitality (Naci et al., 2010), cognitive impairment (Zwibel and Smrtka, 2011) and 
fatigue (Khan et al., 2014), are either not included or are poorly measured by the EDSS. Even in the 
early stages of MS, cognitive impairment may result in a lower quality of life (Glanz et al., 2010), have 
a negative impact upon day-to-day activities (Rao et al., 1991; Kalmar et al., 2008) and lead to a 
reduced ability to work (Rao et al., 1991; Benedict et al., 2005). Persistent or sporadic fatigue also 
leads to a lower quality of life (Khan et al., 2014) (see first-person account below) and affects about 
75% of all people with MS (Lerdal et al., 2007). 
First-person account (Multiple Sclerosis Society UK, 2015) 
What a silly word ‘fatigue’ is. It sounds like ‘I need to have a quick sit-down on this sofa’. In reality it’s 
more like ‘I can hardly move and my brain has shut down on me, I feel like I’ve just had a heavy bout 
of flu’. 
It’s hard to predict when fatigue will strike. Sometimes I have to cancel meeting up with friends, or cut 
short a very happy outing when my energy slumps. I have to build in rest days to avoid a crash-and-
burn episode of fatigue. These make my diary seem fuller than it really is. ‘No I can’t meet on 
Wednesday, it’s got to be a rest day’. I am lucky to have friends who are understanding of fatigue. 
With permission from the Multiple Sclerosis Society 
When making decisions about how healthcare resources should be allocated, it is necessary to 
compare how different diseases affect health-related quality of life. In the cost-effectiveness analyses 
that drive such decisions, a person’s perspective on their state of health is measured using utility, a 
value between 1 (full health) and 0 (death). A number of studies have shown that people with MS 
report a lower utility than the general population, even early in the disease when physical disability is 
minimal, and that they experience a rapid decrease in utility with increasing disability (Figure 4) 
(Kobelt et al., 2006b; Orme et al., 2007; Kobelt et al., 2009; Naci et al., 2010; Zwibel and Smrtka, 
2011). 
Although advancing age can be expected to lead to a decrease in utility, people with MS in the 18–
29-year age group already rate their own health status lower than those aged 80 years or older in the 
general population do. Also, when individuals in the same age group are compared, the average utility 
is about 0.2–0.3 points lower for people with MS compared with the general population (Figure 5) 
(Kobelt and Kasteng, 2009). 
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First-person account (Ploughman et al., 2012) 
My mother is 20 years older than I am and I can’t keep up with her. I do feel that I’ve been cheated. I 
have been made an old woman before my time. 
Many studies have shown that the worsening of symptoms that results from disability progression 
markedly affects day-to-day living and quality of life (Lobentanz et al., 2004; Kobelt et al., 2006a; 
Kobelt et al., 2006c; Miller and Dishon, 2006; Naci et al., 2010). The symptoms that emerge during 
relapses last for weeks to months and also lead to restricted mobility (Parkin et al., 2000), a 
temporary worsening of pain (Parkin et al., 2000), an increased risk of symptoms of depression 
(Moore et al., 2012), a lower quality of life and reduced function (Naci et al., 2010; Oleen-Burkey et 
al., 2012); these are on top of the significant symptom burden that may already have accumulated. 
1.3.2 Multiple sclerosis often results in unemployment 
Unemployment levels among people with MS are higher than those in the general population, even at 
low levels of physical disability (Figure 6) (Kobelt et al., 2006b; Kobelt et al., 2009; Eurostat, 2015). 
This suggests that the ability to work is affected early on; the most likely reasons for this are problems 
such as cognitive decline, fatigue, depression and anxiety, which are not fully captured by the EDSS. 
This observation is supported by real-world evidence (evidence obtained from outside the clinical trial 
setting), which indicates that cognitive impairment (Julian et al., 2008; Ruet et al., 2013) and fatigue, 
as well as problems with hand function and mobility (Julian et al., 2008), are associated with an 
increased likelihood of becoming unemployed. As physical disability progresses, the proportion of 
people with MS who are unemployed rises markedly (Figure 6) (Kobelt et al., 2006b; Kobelt et al., 
2009; Eurostat, 2015). Case studies have shown, however, that the chances of people with MS 
remaining in the workforce can be improved by using approaches that focus on ability (rather than on 
disability), such as adapting working environments, working hours and job roles (Swiss Multiple 
Sclerosis Society, 2011). Indeed, a Europe-wide campaign focusing on supporting sustainable 
employment was launched in March 2015 by the European Multiple Sclerosis Platform (European 
Multiple Sclerosis Platform, 2015a). 
First-person account (Ploughman et al., 2012) 
One of the things that I found difficult was losing friendship because you are no longer in the 
workforce. It becomes a pretty lonely thing. 
1.3.3 Being a caregiver can be a lifetime commitment 
Despite the devastating impact of the disease, the life expectancy of people with MS is reduced by 
only 5–10 years (Bronnum-Hansen et al., 2006; Grytten Torkildsen et al., 2008; Kaufman et al., 2014; 
Marrie et al., 2015); this indicates that many individuals live a long time with substantial disability. As a 
result, nearly one-third of people with MS need care, about 80% of which is provided ‘informally’ by 
unpaid caregivers such as relatives (Hillman, 2013). As the disease progresses, the need for care 
gradually increases. A typical informal caregiver spends more than 4 hours per day on caring 
activities over many years, which is both physically and emotionally draining (Hillman, 2013). Thus, 
the personal costs of disability progression fall not just on people with MS but also on their families. 
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Caregiver account (Borreani et al., 2014) 
My old life has vanished. It’s just me, my husband, and his disease. That’s all. The disease stands 
between me and my husband. I used to work, now my life is dedicated to him. This is all very 
depressing and I don’t know how long I can go on. 
1.4 Costs of multiple sclerosis soar as the disease progresses  
The total costs of MS to society include direct medical and non-medical costs, and indirect costs 
(Figure 7). In Europe, the overall annual cost of MS to society has been estimated at €15.5 billion. 
This represents an average annual cost of €37000 per person with MS (Kobelt and Kasteng, 2009), 
comparable with averages of $52000 (€39000) in the USA (Kobelt et al., 2006a) and AUD 49000 
(€33000) in Australia (Palmer et al., 2013). (For ease of comparison, all monetary values in this 
section have been adjusted to 2010 values using the Consumer Price Index.) 
This annual cost per person is greater than that for other long-term conditions such as asthma 
(Braman, 2006), chronic obstructive pulmonary disease (a collection of chronic lung problems) 
(Chapman et al., 2006; Miravitlles et al., 2013) and diabetes (American Diabetes Association, 2013). 
It is also greater than the annual cost per person of most other brain disorders considered by the 
European Brain Council in a series of economic cost estimates (Olesen et al., 2012), apart from the 
neuromuscular condition Guillain–Barré syndrome (which costs approximately €54000 per person 
(Olesen et al., 2012), about 80% of whom do not have persistent neurological problems (Walling and 
Dickson, 2013) – unlike in MS where accumulated disability is mostly irreversible) (Olesen et al., 
2012). 
As a person with MS becomes more disabled, total societal costs (detailed in Figure 7) increase 
significantly. In Europe, the mean annual cost per person with MS has been estimated at €23000 for 
EDSS score 0.0–3.5, rising as disability increases to €46000 for EDSS score 4.0–6.5 and €77000 for 
EDSS score 7.0–9.5 (Kobelt and Kasteng, 2009). Indirect costs (productivity losses associated with 
sick leave, incapacity to work and early retirement) – and especially informal care costs – increase 
dramatically with increasing disability (Figure 8) (Kobelt et al., 2006b). This additional cost burden 
falls largely outside of the healthcare and social care systems, and a lot of it is borne by people with 
MS and their families. Medicines (pharmaceuticals) comprise a relatively low proportion of total 
societal costs, especially at greater levels of disability (Figure 8) (Kobelt et al., 2006b). 
Relapses also lead to additional costs, only about half of which are borne by the healthcare system 
(for example, inpatient, outpatient and professional care, consultations, tests and medicines) 
(Johansson et al., 2012; Karampampa et al., 2012b; Karampampa et al., 2012c; Karampampa et al., 
2012d; Karampampa et al., 2012e). The cost per relapse was estimated at €3400–9600 in a series of 
recent European studies in people with RRMS and EDSS scores less than 5.0 (Johansson et al., 
2012; Karampampa et al., 2012a; Karampampa et al., 2012b; Karampampa et al., 2012c; 
Karampampa et al., 2012d; Karampampa et al., 2012e; Karampampa et al., 2013; Karabudak et al., 
2015) and at $10100 (€7600) in members of a US patient support group with RRMS (Oleen-Burkey et 
al., 2012). 
These data show that the bulk of the additional costs of disability progression and roughly half of the 
costs of relapses fall outside the healthcare and social care systems. However, in many countries 
these significant societal costs are not considered when treatments for MS are being assessed 
(Section 6.1).  
The following sections of this report outline a therapeutic strategy that has the potential to improve 
outcomes for people with relapsing forms of MS by reducing relapses and disability progression. It 
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could also lead to lower formal and informal care costs and indirect costs, which escalate at higher 
levels of disability. 
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Figure 1. Brain atrophy in many people with MS is faster than usual and proceeds throughout the 
disease course. This example illustrates how brain atrophy may be accelerated in a person with 
untreated MS (De Stefano et al., 2014a), with disease onset at 25 years of age, compared with a 
healthy individual (De Stefano et al., 2016). 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
 
This is an author’s draft of an accepted article submitted and 
published in Multiple Sclerosis and Related Disorders 
DOI: http://www.sciencedirect.com/science/article/pii/S221103481630102X 
 
 
18 
 
 
Figure 2. The damage caused by MS typically leads to relapses followed by progressive disease. a. 
The brains of people with MS shrink (atrophy) more rapidly than usual as a result of damage caused 
by the disease. b. The brain can use its neurological reserve to compensate for damage by 
remodelling itself. However, when neurological reserve is used up, the clinical symptoms of the 
disease may progress. c. MS causes lesions – acute areas of damage to the brain and spinal cord 
that accumulate over time. If a lesion noticeably disrupts nerve function, it leads to a relapse (an 
attack of clinical symptoms). d. A typical MS disease course involves relapses, followed by 
progressive disease. e. A person with MS may have a variety of diagnoses over time (see text for 
details), but disease-modifying therapies are effective only in the early stages when relapses are still 
This is an author’s draft of an accepted article submitted and 
published in Multiple Sclerosis and Related Disorders 
DOI: http://www.sciencedirect.com/science/article/pii/S221103481630102X 
 
 
19 
 
present. 
CIS, clinically isolated syndrome; NRSPMS, non-relapsing secondary progressive multiple sclerosis; RIS, 
radiologically isolated syndrome; RRMS, relapsing–remitting multiple sclerosis; RSPMS, relapsing secondary 
progressive multiple sclerosis. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Figure 3. The symptoms of MS(Compston and Coles, 2008; Giovannoni et al., 2012) are distressing 
and exhausting. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Figure 4. People with MS report a rapid decline in health status (utility) even early in the disease 
course; this continues to worsen with increasing disability (Kobelt et al., 2006b; Kobelt et al., 2009). 
EDSS, Kurtzke Expanded Disability Status Scale. 
Reproduced and adapted from J Neurol Neurosurg Psychiatry, Kobelt G, Berg J, Lindgren P et al. 77, 918–26, © 
2006 with permission from BMJ Publishing Group Ltd.  
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Figure 5. People with MS report a lower average health status (mean utility) than those of a similar 
age in the general population (Kobelt and Kasteng, 2009). 
EDSS, Kurtzke Expanded Disability Status Scale. 
Reproduced and adapted with permission from Gisela Kobelt from Kobelt G, Kasteng F. Access to innovative 
treatments in multiple sclerosis in Europe. The European Federation of Pharmaceutical Industry Associations 
(EFPIA) 2009 (Kobelt and Kasteng, 2009). © Gisela Kobelt 2009. 
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Figure 6. The proportion of people with MS who are in employment is greatly reduced even at low 
levels of physical disability, and decreases markedly as disability increases (Kobelt et al., 2006b; 
Kobelt et al., 2009; Eurostat, 2015). 
EDSS, Kurtzke Expanded Disability Status Scale. The range (shaded areas) and median (dotted lines) of the 
proportion of the general population in employment are shown for the age groups stated for the countries listed. It 
should be noted that, in many of these countries, people retire at less than 65 years of age. 
Reproduced and adapted from J Neurol Neurosurg Psychiatry, Kobelt G, Berg J, Lindgren P et al. 77, 918–26, © 
2006 with permission from BMJ Publishing Group Ltd. 
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Figure 7. The total societal costs of MS are borne mainly by health and social care services, people 
with MS and their families. 
DMT, disease-modifying therapy; GP, general practitioner (family or primary care physician). 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Figure 8. As disability progresses, informal care (black) and indirect costs (dark orange) increase 
dramatically and greatly exceed the cost of pharmaceuticals (medicines; light orange) (Kobelt et al., 
2006b). 
Average annual costs per person with MS a in the UK and b in Germany at EDSS scores 2.0 and 6.5, converted 
to 2010 euros. Examples of items in each cost category can be found in Figure 7. Percentages have been 
independently rounded. 
EDSS, Kurtzke Expanded Disability Status Scale. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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2. Speed up referral and diagnosis 
Key points 
 The earlier that MS can be diagnosed, the sooner treatment can be initiated. 
 Ideally, people with suspected MS should be referred for diagnosis to a neurologist with a 
special interest, and expertise, in MS and an experienced team and facilities at their 
disposal. Such specialists are best placed to diagnose, treat and manage MS. 
 It is currently possible to diagnose MS earlier than ever before – 10 times more rapidly than 
in the 1980s – by using evidence from magnetic resonance imaging (MRI) brain scans in 
conjunction with clinical assessments. 
 However, significant delays can still occur between noticing the first symptoms and 
receiving a diagnosis. Such delays could be reduced by improving awareness of MS 
among the general public and healthcare professionals who make referrals and by 
improving access to specialist MS healthcare professionals and diagnostic equipment. 
2.1 Time is critical to preserving brain volume and physical function 
As discussed in Section 1.2.1, many people with CIS (Zivadinov et al., 2006) and early MS already 
experience brain atrophy more rapidly than the general population (Figure 1) (De Stefano et al., 
2010). This loss of brain tissue is often subclinical (not accompanied by clinical symptoms), owing to 
repair mechanisms in the CNS and neurological reserve that enable the brain to reorganize itself and 
reroute pathways to avoid damaged areas, even when repair is incomplete (Rocca et al., 2003; Rocca 
and Filippi, 2007). If the brain were not so flexible, clinical symptoms of MS would become apparent 
sooner; this remarkable ability to compensate means that ongoing damage may go unrecognized until 
neurological reserve has deteriorated significantly. 
In the absence of a cure for MS, the aim of starting treatment with a DMT should be to reduce 
subclinical disease activity, preserve brain volume and slow or prevent disability progression (Gold et 
al., 2010; Damal et al., 2013). Early diagnosis means that early DMT initiation can be accompanied by 
other appropriate steps to preserve brain tissue and optimize brain health (for example, exercise, 
smoking cessation, weight loss and control of comorbidities [other diseases present alongside MS] 
such as high blood pressure). This approach maximizes the chances of altering the disease course 
before further relapses or disability progression occur (Section 3). 
2.2 Early referral to a neurologist is essential 
Generally, a person experiencing symptoms compatible with early MS will go initially to their family 
doctor or primary care physician or to a hospital. From there, they should be referred urgently to a 
neurologist – a doctor who specializes in diseases of the nervous system. 
Neurology is a wide-ranging discipline that has grown in complexity over the years, resulting in sub-
specialization. For example, a world-leading neurology department of a large hospital may offer 
specialist clinics in the areas of epilepsy, headache, motor neurone disease, movement disorders 
(such as Parkinson’s disease), peripheral nerve disorders, and MS (sometimes combined with other 
autoimmune disorders under the term ‘neuroimmunology’) (Barts Health NHS Trust, 2015). 
2.2.1 Referral to an MS neurologist is desirable 
MS is a complex disease, and neurologists who specialize in MS (MS neurologists) (Scolding et al., 
2015), together with their multidisciplinary teams (Table 1), are best placed to provide routine 
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diagnosis and an integrated approach to specialist care and management (Biogen Idec Inc., 15 
August 2014; Genzyme Corporation, 17 October 2014; De Broe et al., 2001; While et al., 2009; 
Mynors et al., 2012; Adamec et al., 2013; MS Society, 2013; Multiple Sclerosis International 
Federation, 2013a; Novartis Pharma GmbH, Revised 24 July 2014; Biogen Idec Inc., Revised: 3 
December 2014; Genzyme Corporation, Revised: 14 November 2014; Biogen Idec Ltd., Revised: 18 
December 2014; Revised: 23 December 2014; Genzyme Therapeutics Ltd, Revised: 25 March 2014; 
Sanofi-aventis Groupe, Revised: 28 November 2014; Novartis Pharmaceuticals Corporation, Revised: 
30 April 2014). MS neurologists have broad experience of the long-term management of MS and the 
fast pace of changes in understanding of the disease, diagnostic criteria, treatment options and 
monitoring processes.  
However, access to MS healthcare professionals, specialist teams and diagnostic facilities varies 
widely across the globe. There are about 120 times more MRI scanners and neurologists per capita in 
high-income countries than in low-income countries – and the numbers per capita vary considerably 
even within high-income countries – according to a 2013 survey (Multiple Sclerosis International 
Federation, 2013a). In addition, the existence of multidisciplinary hospital-based teams was reported 
by respondents from 36 of the 52 countries for which the survey question was completed (Multiple 
Sclerosis International Federation, 2013a). These data indicate that the existence of specialist 
personnel or facilities does not necessarily imply that they are readily accessible in practice. 
First person account(Colhoun et al., 2015) 
My MS nurse is my lifeline. Without her I would be lost. She gives me as much or as little as I request. 
Modern technology can be used to address some of the inequalities in access to diagnostic services 
and ongoing specialist care for people with MS, as indicated by a number of pilot studies in the field of 
telemedicine (remote diagnosis, treatment or ongoing management using telecommunications 
technology) (Table 2) (Finkelstein et al., 2008; Kane et al., 2008; Luccichenti et al., 2010; Zissman et 
al., 2012; Ortiz-Gutierrez et al., 2013; Wood et al., 2013; Turner et al., 2014; Khan et al., 2015). 
Although telemedicine has proved to be extremely useful for servicing remote populations, it does not 
solve the problem of a low density of services per capita. 
Technology can also provide greater access to specialist training for MS healthcare professionals. For 
example, 2379 nurses from 30 countries across the globe (Winslow, 2015) have registered for the MS 
Nurse Professional course, led by the European Multiple Sclerosis Platform in collaboration with the 
International Organization of Multiple Sclerosis Nurses and Rehabilitation in MS (European Multiple 
Sclerosis Platform, 2015b), in the 2 years to March 2015. 
2.3 Delays in the referral pathway are common 
Delays between the onset of symptoms and MS diagnosis can occur at two key points. Delays 
between the onset of symptoms and an initial consultation with a healthcare professional are common 
(Fernandez et al., 2010; Adamec et al., 2013) and can last more than 1 year (Fernandez et al., 2010). 
This indicates the need to raise awareness of the symptoms of MS among the general population 
(Fernandez et al., 2010).  
Further delays may then occur before eventual diagnosis by a specialist healthcare professional 
(neurologist or MS neurologist). In addition to waiting lists that inevitably occur when the numbers of 
neurologists per capita are low, such delays can also result from non-availability of diagnostic tools 
such as MRI scanners and lumbar puncture, from administrative issues (for example, long waiting lists 
for neurology services after referral) (Kelly et al., 2011) and from lack of awareness among family or 
primary care physicians (Figure 9) (Fernandez et al., 2010; Kelly et al., 2011; Adamec et al., 2013).  
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There is evidence of a relationship between delays in referral to an MS neurologist and disability level 
at the time of the first visit: the longer the delay, the greater the initial disability level at that time 
(Kingwell et al., 2010). The effects of delays between diagnosis and treatment initiation are described 
in Section 3. 
First-person account(Jarvis, 2012) 
I started getting a lot of pain in my legs and lower back. Along with the pain, I was getting weird nerve 
sensations in my legs and my legs felt as though they were getting weaker and weaker. This 
continued from 2003 to this day. I saw orthopaedic specialists on nine occasions and they put the 
problems down to the sciatic nerve. In 2010 ... I registered with a new doctor ... . He told me he was 
referring me to a neurosurgeon [sic] to get this checked out properly. In early 2011, I was sent for full 
body MRI scans and lumbar punctures ... finally ... [in] February 2012, I was diagnosed with primary 
progressive MS ... . I have fought for 9 years to try and work out what was going on in my legs. 
2.4 Magnetic resonance imaging evidence assists early diagnosis 
Symptoms similar to those of MS appear in many other conditions. Therefore when making a 
diagnosis, clear differentiation between these other conditions and MS is crucial. Being diagnosed 
with a chronic, unpredictable, progressive incurable disease such as MS has huge personal 
implications, including reduced employability, increased anxiety and mental distress, and years of 
taking medicines (Rolak and Fleming, 2007). 
2.4.1 Early diagnostic criteria required two or more acute clinical relapses 
Historically, it was difficult to diagnose MS because lesions in the CNS could only be observed 
directly on autopsy. The early diagnostic criteria for MS (the Schumacher(Schumacher et al., 1965) 
and Poser(Poser et al., 1983) criteria, published in 1965 and 1983, respectively) therefore relied on 
directly observable events: a diagnosis of clinically definite MS required at least two acute clinical 
relapses. The Poser criteria also incorporated evidence from electrical measurements of brain activity 
when certain nerves are stimulated (‘evoked potentials’) and lumbar puncture to help to support the 
clinical diagnosis (Poser et al., 1983). 
2.4.2 Evidence from brain scans now allows faster and more accurate diagnosis 
With the advent of MRI it became possible to classify lesion patterns in the CNS that are suggestive 
of MS. As understanding of MRI improved, the McDonald diagnostic criteria were introduced in 2001 
(McDonald et al., 2001) and further refined in 2005 (Polman et al., 2005; Swanton et al., 2007) and 
2010 (Polman et al., 2011). The McDonald criteria allow a diagnosis of MS to be made in a person 
who has had just one relapse, by incorporating evidence from MRI scans. The criteria recognize that 
diagnostic certainty can be increased when lesions are observed in typical locations and when they 
can be shown to have appeared over a period of time (rather than all at once) (Montalban et al., 
2010). 
As a result of incorporation of MRI evidence into the diagnostic criteria, people with MS can have their 
condition diagnosed more rapidly than was previously possible and in a more sensitive and consistent 
way (Zipoli et al., 2003). The number of people whose MS is accurately diagnosed within 1 year of 
their first relapse more than doubles (Dalton et al., 2002) or triples (Tintore et al., 2003) using the 
original McDonald criteria compared with the Poser criteria. In addition, a diagnosis can be 
established from the earliest MRI scans in about one in five people who have experienced a single 
relapse using the 2010 McDonald criteria (Runia et al., 2013). It should be noted, however, that the 
McDonald criteria are not always used consistently in clinical practice (Hawkes and Giovannoni, 
2010). 
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2.4.3 Greater diagnostic certainty enables earlier treatment  
The McDonald criteria are now widely accepted and used to establish a diagnosis of MS. Of the 105 
countries for which data were provided in a 2013 global survey, a version of the McDonald criteria 
was reported as being used in 92% (Multiple Sclerosis International Federation, 2013g). Real-world 
evidence from the USA shows that the average delay from symptom onset to diagnosis has fallen 10-
fold, from 7.2 years in 1980–1984 to 0.63 years in 2000–2004 (Table 3) (Marrie et al., 2005). In the 
same time period, the proportion of people who had moderate or severe disability (as opposed to mild 
disability) on their initial visit to a healthcare professional fell from over 50% to about 25% (Marrie et 
al., 2005). Early diagnosis means that early treatment is possible – which will improve the long-term 
prognosis for people with MS by reducing subsequent damage to the CNS and preventing further 
unnecessary clinical relapses or disability progression (Section 3). 
The evolution and subsequent implementation of MS diagnostic criteria is an excellent example of the 
use of an evidence base to improve clinical practice and outcomes for people with MS. Despite clear 
diagnostic evidence, however, the prescribing guidelines for MS issued by national healthcare 
authorities in some countries still require a person to experience two clinical relapses, and in some 
cases disabling relapses, before a DMT can be initiated (Section 3.3.1). This means that further 
irreversible damage to the CNS can occur, both during the time spent waiting for a second relapse 
and as a result of the relapse itself. 
2.5 Recommendations 
Delays in the diagnosis of MS should be minimized as these can result in irreversible disability 
progression. 
 Educate the general public to take prompt action if early symptoms of MS develop, 
by visiting a healthcare professional. Awareness campaigns that highlight the typical 
initial symptoms, the negative impact of delaying treatment and the personal and societal 
costs of the disease would support this. 
 Educate family and primary care physicians about the importance of promptly referring 
people with suspected MS to a neurologist, and ultimately to a specialist clinic, to speed up 
diagnosis and treatment initiation. 
 Recommend that general neurologists refer people suspected of having the disease to 
specialist MS neurologists. 
 Improve access to specialist care for MS: make diagnostic and monitoring procedures 
more widely accessible, increase the numbers of healthcare professionals who specialize 
in the management of MS, and ensure that these specialists provide prompt diagnostic and 
support services for people with suspected MS and those who have been newly diagnosed 
with the disease. 
 Adopt the latest accepted diagnostic criteria, in order to diagnose MS as early as 
possible. 
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Specialist aspect Description 
MS neurologists have access to 
specialist equipment and personnel 
MS neurologists have direct access to specialist diagnostic and 
monitoring equipment (for example, MRI scanners) and often 
work with experienced and MS-specialized staff, including 
nurses, physiotherapists, psychologists and others 
MS neurologists have knowledge 
of rapidly evolving treatment 
options 
MS neurologists have in-depth knowledge of the latest 
techniques and treatment options. In the last 5 years alone, five 
new DMTs were approved for use in the USA (Biogen Idec Inc., 
15 August 2014; Genzyme Corporation, 17 October 2014; 
Biogen Idec Inc., Revised: 3 December 2014; Genzyme 
Corporation, Revised: 14 November 2014; Novartis 
Pharmaceuticals Corporation, Revised: 30 April 2014) and 
Europe (Novartis Pharma GmbH, Revised 24 July 2014; Biogen 
Idec Ltd., Revised: 18 December 2014; Revised: 23 December 
2014; Genzyme Therapeutics Ltd, Revised: 25 March 2014; 
Sanofi-aventis Groupe, Revised: 28 November 2014); the 
situation is similar in other geographical regions 
MS specialist nurses can 
implement programmes and 
support people with MS 
MS specialist nurses are the key staff members in many MS 
clinical services. Their varied roles include implementation of 
DMT safety and effectiveness monitoring programmes, support 
and counselling, case management, symptom screening and 
management, and provision of education about MS disease and 
DMTs. There is evidence that MS specialist nurses are highly 
valued by people with MS (Colhoun et al., 2015), can provide 
emotional support (While et al., 2009) and can improve their 
knowledge, confidence and ability to cope (De Broe et al., 2001)  
Involving MS specialist nurses can 
save money 
The potential for economic savings has been illustrated in a 
number of case studies when MS specialist nurses were 
involved in ongoing care, through reduced numbers of hospital 
admissions and neurologist appointments (Mynors et al., 2012) 
Specialist clinics enable rapid 
diagnosis 
Diagnosis of MS and CIS was more rapid at a specialist clinic 
compared with non-specialist options for those suspected of 
having demyelinating diseases (that is, diseases in which the 
sheath surrounding the nerves is damaged) (Adamec et al., 
2013) 
Access to MS healthcare 
professionals increases the 
likelihood of people with MS taking 
a DMT 
People with MS were more than twice as likely to be taking a 
DMT if they had access to an MS neurologist or specialist nurse, 
according to a 2013 UK survey. In Northern Ireland, a region 
where people with MS are invited to see a neurologist or MS 
specialist nurse for a twice-yearly review (unlike in the rest of the 
UK), 70% more people with MS eligible to receive a DMT were 
taking one compared with the national average (MS Society, 
2013) 
A multidisciplinary team offers an 
integrated approach to care where 
different aspects of the disease are 
managed by specialists 
Team members may include: MS neurologist, MS specialist 
nurse, physiotherapist, ophthalmologist, pharmacist, clinical 
psychologist, psychiatrist, occupational therapist, speech 
therapist, pain management specialist, chiropodist/podiatrist, 
urologist, continence advisor, social worker, dietician (Multiple 
Sclerosis International Federation, 2013a) 
Table 1. Neurologists with a special interest in MS (described above as MS neurologists) and their 
multidisciplinary teams have extensive experience, knowledge and facilities at their disposal. 
CIS, clinically isolated syndrome; DMT, disease-modifying therapy; MRI, magnetic resonance imaging. 
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Type of telemedicine resource Outcome 
Analysis of lesions on MRI scans 
using software that runs in a web 
browser 
Similar results to those obtained using conventional software 
(Luccichenti et al., 2010) 
Remote assessment of disability Clinically valid information and similar total EDSS scores 
compared with ‘in-person assessments’ using a 
videoconference link (Kane et al., 2008) or low-cost webcam 
(Wood et al., 2013) 
Home-based rehabilitation 
programmes 
Improvements in function, such as walking, balance (Finkelstein 
et al., 2008) and postural control (Ortiz-Gutierrez et al., 2013) 
Low-level evidence for reduction in impairments (such as fatigue, 
pain and insomnia) and improvement in functional activities and 
participation, based on a systematic review of nine randomized 
controlled trials (Khan et al., 2015) 
Brief telecounselling sessions and 
home monitoring 
Better adherence to medication than that found for people 
who did not receive these services (Turner et al., 2014) 
Home monitoring Less severe symptoms than in those who did not receive the 
service; additionally, two-thirds of those in the telecare home-
monitoring group had a decrease in medical costs of at 
least 35% (Zissman et al., 2012) 
 
Table 2. Telemedicine can help to improve access to diagnostic services and ongoing specialist care 
by extending services to remote populations, as indicated by the results of several pilot studies. 
EDSS, Kurtzke Expanded Disability Status Scale; MRI, magnetic resonance imaging. 
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Figure 9. Delays between the initial onset of MS symptoms and diagnosis are common (Fernandez et 
al., 2010; Kelly et al., 2011; Adamec et al., 2013) and can last more than 2 years (Fernandez et al., 
2010). 
MRI, magnetic resonance imaging. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Onset of 
symptoms 
Mean (SD) delay (years) 
from onset of symptoms 
to diagnosis 
1980–1984 7.2 (5.7) 
1985–1989 5.3 (4.4) 
1990–1994 3.7 (3.2) 
1995–1999 1.8 (1.7) 
2000–2004 0.63 (0.8) 
 
Table 3. There has been a 10-fold decrease in the delay between the onset of MS symptoms and 
diagnosis since 1980 in the USA (Marrie et al., 2005). 
SD, standard deviation. 
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3. Intervene early to maximize lifelong brain health 
Key points 
 The goal of treating MS should be to preserve brain tissue and maximize lifelong brain 
health by reducing disease activity. 
 There is a lot of evidence to support the therapeutic strategy of early intervention with a 
DMT. This should accompany measures to encourage a ‘brain-healthy’ lifestyle as part of a 
comprehensive approach to treatment. 
 However, initiating treatment with a DMT is often delayed and subject to restrictions in 
licensing, prescribing guidelines and reimbursement policies. 
 Treatment options are rapidly evolving and many DMTs are now available. They are not all 
equally effective in all people with MS, and they have a variety of side-effect profiles. 
 The choice to initiate treatment should be an informed, shared decision between the person 
with MS and their clinician, and should consider all appropriate DMTs. The disease course, 
values, needs, limitations and lifestyle of the person with MS should all be assessed in 
parallel with the potential benefits and risks of specific DMTs. 
3.1 Intervention should aim to maximize brain health and physical function 
3.1.1 Early intervention is key 
MS causes irreversible damage to the brain and spinal cord. Although repair mechanisms and 
remodelling of the CNS can partially compensate for a while, these mechanisms eventually fail to 
keep up with the damage caused by inflammatory disease activity. Ultimately neurological reserve – 
the capacity that the CNS has to compensate for injury by remodelling itself – is exhausted (Figure 
2b). The clinical consequences of MS then become clear – steady increases in physical and mental 
disability without remissions, as seen in people who have transitioned to SPMS.  
Following this transition, the opportunity to change the course of the disease is diminished. No DMTs 
have been approved worldwide for NRSPMS, and – even if treatment were possible – reversal of 
persistent disability is highly unlikely. Additionally, the depletion of neurological reserve means that 
fewer resources remain to combat the cognitive and physical effects of normal age-related brain 
atrophy (Schwartz et al., 2013). Effective DMT and lifestyle interventions must, therefore, be initiated 
as soon as the disease is diagnosed in order to protect neurological reserve and maximize lifelong 
brain health. This approach is in line with the principles on brain health established by the World 
Federation of Neurology and promoted across a number of brain and mental health disease areas by 
the World Brain Alliance (World Federation of Neurology, 2015). 
3.1.2 Treating and managing multiple sclerosis requires a comprehensive approach  
Maximizing lifelong brain health is equivalent to preserving neurological reserve. The results of 
recent research imply that neurological reserve has two components: brain reserve (brain volume) 
and cognitive reserve (see Box). Preserving brain volume (Kalincik et al., 2012; Popescu et al., 2013; 
Sormani et al., 2014; Uher et al., 2014; Radue et al., 2015) and cognitive reserve (Schwartz et al., 
2013) protects against disability progression, and these two factors independently protect against 
disease-related cognitive decline (Sumowski et al., 2013). The therapeutic strategy in MS should aim 
to preserve as much brain reserve and cognitive reserve as possible by using DMTs to slow down the 
disease course and by adopting a ‘brain-healthy’ lifestyle. 
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Neurological reserve comprises brain reserve and cognitive reserve 
Brain reserve can be thought of as the physical quantity of brain tissue present. Initial brain volume is 
genetically and/or congenitally determined (Bartley et al., 1997; Tramo et al., 1998), and it is normal 
for healthy adults to experience some brain atrophy as they age (Figure 1). It has been shown that 
elderly people with greater brain reserve (i.e. who have larger brains) experience cognitive 
impairment later than those with smaller brains (Reynolds et al., 1999; Tisserand et al., 2001; 
MacLullich et al., 2002; Farias et al., 2012). 
Cognitive reserve can be viewed as the ability of the brain to process tasks and actively compensate 
for physical damage (Stern, 2002). All other things being equal, people with MS who have a high 
cognitive reserve lose less cognitive function than those with a low cognitive reserve for the same 
amount of physical damage (measured in terms of brain atrophy (Pinter et al., 2014; Sumowski et al., 
2014; Modica et al., 2016) or lesions (Pinter et al., 2014; Sumowski et al., 2014)). 
Cardiovascular fitness correlates with brain volume and cognitive reserve (processing speed) in 
people with MS (Prakash et al., 2010), and improving it through aerobic exercise should be part of 
managing MS. Avoidance of smoking should be another component of a ‘brain-healthy’ lifestyle. 
Cigarette smoking is associated with decreased brain volume in people with MS (Kappus et al., 
2016), as well as with higher relapse rates (B. et al., 2010), increased disability progression (Pittas et 
al., 2009; B. et al., 2010), increased cognitive impairment(Ozcan et al., 2014) and reduced survival 
(Jick et al., 2015) compared with not smoking. Additionally, smokers with CIS are nearly twice as 
likely as non-smokers with CIS to develop further inflammatory lesions and, thus, MS (Di Pauli et al., 
2008). Limiting the use of alcohol is also important, because there is evidence that unsafe levels of 
drinking (currently or in the past) lead to reduced survival in people with MS (Jick et al., 2015). 
Activities that enhance cognitive reserve by being intellectually enriching (such as education, 
reading, hobbies and creative expression) have been shown to protect against cognitive impairment 
in MS when pursued over a lifetime (Sumowski et al., 2009; Sumowski et al., 2010; Pinter et al., 2014; 
Sumowski et al., 2014; Modica et al., 2016) and should be prioritized day-to-day. 
Minimizing comorbidities (other diseases present alongside MS) will help to reduce their negative 
effect on the MS disease course and to limit the potential for disability unrelated to MS, which can add 
to the overall impairment burden. 
 In people with MS, high blood pressure and heart disease are both associated with lower 
brain volume, and obesity is associated with higher lesion numbers (Kappus et al., 2016). 
 High blood pressure, type 2 diabetes, dyslipidaemia (high levels of cholesterol and/or fat in 
the blood) and peripheral artery disease (narrowing of the arteries outside of the heart and 
brain) are all associated with greater disability progression if they co-exist at any time in the 
MS disease course (Tettey et al., 2014); so too are vascular diseases in general (those 
affecting the blood vessel system) (Marrie et al., 2010a).  
 Heart disease, influenza, pneumonia, urinary tract infections and cancer are all predictors 
of reduced survival among people with MS (Jick et al., 2015). 
To summarize, maximizing lifelong brain health in MS involves a comprehensive approach that 
incorporates lifestyle measures such as aerobic exercise, avoidance of smoking and excessive 
alcohol consumption, activities that enhance cognitive reserve, and steps to minimize comorbidities, 
in addition to intervention with a DMT (the focus of the remainder of this section). 
This is an author’s draft of an accepted article submitted and 
published in Multiple Sclerosis and Related Disorders 
DOI: http://www.sciencedirect.com/science/article/pii/S221103481630102X 
 
 
36 
 
3.2 A lot of evidence supports early intervention with a DMT 
Long-term studies clearly show that early intervention with a DMT is more likely than late intervention 
to lead to a better outcome in people with CIS and RRMS (Figure 10) (Miller, 2004). There are three 
main components to the body of evidence supporting this. 
 In people with a diagnosis of CIS, treatment with a DMT increases the time to a second 
relapse (that is, conversion to RRMS under any diagnostic criteria) and improves MRI 
outcomes, including brain atrophy rate (Table B.1) (Jacobs et al., 2000; Comi et al., 2001; 
O'Connor, 2003; Filippi et al., 2004; Kappos et al., 2006a; Comi et al., 2009; Comi et al., 
2012; Miller et al., 2014). 
 In people with a diagnosis of CIS, initiating treatment with a DMT early in the disease 
course is associated with better long-term outcomes than delaying treatment (Table B.2) 
(Kinkel et al., 2012; Comi et al., 2013; Edan et al., 2015). 
 In people with a diagnosis of RRMS, initiating treatment with a DMT early in the disease 
course is associated with better long-term outcomes than delaying treatment (Table B.3) 
(Prisms Study Group and University of British Columbia MS/MRI Analysis Group, 2001; 
Johnson et al., 2005; Kappos et al., 2006b; Rovaris et al., 2007; Trojano et al., 2007; 
Trojano et al., 2009; Bermel et al., 2010; Ebers et al., 2010; Goodin et al., 2012a; Goodin et 
al., 2012b; Agius et al., 2014; Kappos et al., 2015). 
It is important to note that, nowadays, many of the participants in the CIS trials summarized in Tables 
B.1 and B.2 would have been diagnosed with RRMS according to the 2010 revision of the McDonald 
diagnostic criteria (Costello et al., 2015). Therefore, this evidence also supports early treatment in 
RRMS.  
In the majority of studies summarized in Tables B.2 and B.3, participants were randomly chosen to 
receive either a DMT or placebo (a ‘dummy’ treatment with no therapeutic effect) for an initial period, 
followed by a DMT for an extended period. These ‘placebo-switch’ studies therefore show the 
difference between initiating a DMT early in the disease course and later. 
Further evidence that DMTs are most effective early in the disease course is provided by a recent 
meta-analysis of published randomized clinical trials in RRMS. This showed that DMTs are more 
effective at slowing disability progression from MS in younger people than in older people; they also 
reduce the relapse rate most effectively in younger people (rather than older people), in patients with 
low EDSS scores (rather than high scores) and in those with active lesions (i.e. lesions that are 
currently inflamed) rather than no active lesions (Signori et al., 2015). 
Support for early treatment in RRMS is also provided by real-world evidence from databases and 
registries (Table B.3) (Trojano et al., 2007; Trojano et al., 2009). In addition, for people with CIS, an 
analysis of data from an international registry shows that the greater the length of time spent taking a 
DMT within 12 months of onset, the lower the risk of a sustained increase of at least 1 point on the 
EDSS in the same time period (Jokubaitis et al., 2015). Furthermore, data from the Swedish registry 
indicate that earlier treatment with a DMT is associated with slower disability progression (from 
diagnosis of MS to EDSS score ≥ 4.0) than later treatment (Kavaliunas et al., 2015). 
Initiating treatment with a DMT “as early as possible in eligible patients” is also recommended in the 
2015 guidelines from the Association of British Neurologists (ABN) (Scolding et al., 2015). Once a 
transition from RRMS to SPMS has occurred, however, DMTs become ineffective at preventing 
disability progression (Secondary progressive efficacy clinical trial of recombinant interferon-beta-1a 
in MS study group, 2001; Cohen et al., 2002; Panitch et al., 2004), although some clinical trials have 
demonstrated significant effects on the relapse rate (Secondary progressive efficacy clinical trial of 
recombinant interferon-beta-1a in MS study group, 2001; Cohen et al., 2002), number of new lesions 
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(Li et al., 2001; Cohen et al., 2002; Panitch et al., 2004) and total lesion volume on MRI (Li et al., 
2001; Panitch et al., 2004). To date, no DMTs have been approved for PPMS, and the only DMT to 
have been approved in a small number of jurisdictions for NRSPMS has since been removed from the 
market in the USA. 
3.2.1 Disease-modifying therapies are not all equally effective 
During the 1990s, several DMTs were approved for relapsing forms of MS; in this report these are 
collectively referred to as ‘established DMTs’. Real-world evidence of their long-term effectiveness is 
mixed; some studies report that a particular class of established DMT can slow (but not prevent) 
disability progression (Trojano et al., 2007; Trojano et al., 2009) and conversion to SPMS (Trojano et 
al., 2007; Tedeholm et al., 2013), but others report no effect on disability progression (Shirani et al., 
2012) or on the risk of developing SPMS (Zhang et al., 2015). The results of these studies indicate 
that established DMTs are, at best, modestly effective in altering the natural disease course of MS. 
From the 2000s onwards, several ‘newer DMTs’ have been developed and approved. A number of 
these have been shown to be more effective at reducing disability progression, relapse rate and/or 
burden of lesions when compared head-to-head with established DMTs in clinical trials (Rudick et al., 
2006; Coles et al., 2008; Cohen et al., 2010; Cohen et al., 2012; Coles et al., 2012a; Coles et al., 
2012b). (It should be noted that many participants in clinical trials are newly diagnosed with MS and 
are therefore starting treatment with a newer DMT.) Some newer DMTs that have been approved for 
clinical use have not been subject to head-to-head trials but have instead been compared with 
placebo (Polman et al., 2006; O'Connor et al., 2011) or tested in a study that was set up to include an 
established DMT as a reference arm rather than a direct comparator (Fox et al., 2012). Furthermore, 
a number of other DMTs are in various stages of development – a fact that highlights the increasing 
complexity of MS management and the need for early specialist referral. 
Each of the newer DMTs is associated with a particular set of benefits and risks (e.g. possible side 
effects) and sits in a unique class of drugs. They also have a variety of mechanisms of action (the 
biochemical interactions through which drugs mediate their effects), formulations (ways in which the 
active drug is combined with other ingredients to make the final product) and routes of delivery (for 
example, pills, injections, infusions). It is therefore not always straightforward to choose the DMT that 
is most appropriate to the disease course, values, needs, limitations and lifestyle of each person with 
MS (Section 3.5). 
3.3 Disease-modifying therapy is often started late, with restricted choice 
3.3.1 Treatment initiation criteria may lag behind diagnostic criteria 
The revised McDonald (2010) diagnostic criteria enable an MS diagnosis to be made on the basis of 
one attack (relapse) and MRI evidence from a baseline scan (Section 2.4.2). However, in a 2013 
global survey of 106 countries, responders from 14 of the 27 countries for which data were provided 
on criteria for initiating DMT in people diagnosed with RRMS reported that these included the 
requirement for at least two clinically significant relapses within 2 years (Multiple Sclerosis 
International Federation, 2013f). This reflects the Poser diagnostic criteria, which have been obsolete 
for over a decade since the widespread adoption of the McDonald criteria. 
Prescribing guidelines governing DMT initiation should evolve in parallel with diagnostic criteria in 
order to prevent unnecessary loss of cognitive reserve, loss of brain tissue, deterioration in brain 
health and disability progression as a result of waiting for further relapses to occur before starting 
treatment. 
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3.3.2 Initial treatment options may be restricted 
Once the decision has been made to initiate treatment, the choice of initial DMT is influenced by 
several factors, including DMT licensing, prescribing guidelines, reimbursement, the disease course 
and the personal attitudes, knowledge and life choices of people with MS and their clinicians (Table 
4) (Freedman et al., 2013; Multiple Sclerosis International Federation, 2013f; Wilsdon et al., 2013). 
Even if several initial DMT options have been approved by regulatory authorities, national/local 
prescribing guidelines and reimbursement policies may curtail genuine choice. Some regulators and 
insurers impose treatment sequence restrictions, only allowing people with MS access to some DMTs 
after they have first experienced treatment failure on an established DMT. This means that a 
particular DMT may be available for initial use according to its licence, but not be accessible in 
practice – as illustrated in the following examples. 
 In the USA, some insurance companies require a person with MS to experience treatment 
failure on a DMT from their ‘preferred formulary’ (typically a less-expensive established 
DMT) before they will reimburse the cost of a different DMT (Edlin and Sonnenreich, 2008; 
Owens, 2013). 
 In Spain and Italy, prescribing guidelines and formularies operate at a regional level, and 
the DMTs available for initial use may differ from the list of nationally reimbursed DMTs 
(Multiple Sclerosis International Federation, 2013f; Wilsdon et al., 2013).  
 National reimbursement guidelines in a number of European countries place greater 
restrictions on the circumstance under which a particular newer DMT will be funded than 
the licence issued by the European Medicines Agency (EMA) (Section 6.2.2) (Wilsdon et 
al., 2013). 
 In some countries, no DMT costs are reimbursed by the government or insurance 
companies, and in others, only established DMTs are funded (Multiple Sclerosis 
International Federation, 2013e; d; c; b). This is discussed further in Section 6.2.1. 
3.4 How is treatment initiated in clinical practice? 
MS is a rapidly evolving specialty, and the publication dates of studies that investigate how treatment 
is initiated lag behind the available DMT options. According to the results of a number of studies, the 
most recent of which includes data from 2011, many people with MS do not start treatment with a 
DMT (Table 5) (Margolis et al., 2011; Visser and van der Zande, 2011; Jokubaitis et al., 2013; Phillips 
et al., 2015), and most of those who do so receive an established DMT (Table 6) (Tornatore et al., 
2012; Bonafede et al., 2013; Jokubaitis et al., 2013; Biogen Idec Limited, Revised 22 December 2014; 
Novartis Pharma GmbH, Revised 24 July 2014; Genzyme Corporation, Revised: 14 November 2014; 
Genzyme Therapeutics Ltd, Revised: 25 March 2014). Although these results probably reflect clinical 
practice at the time, a number of newer DMTs have been approved since these studies were 
conducted; some of these DMTs have an evidence base that supports superior efficacy to that of 
established DMTs. Indeed, recently published data from Australia show newer DMT use rising from 
8% of total DMT use in 2011 to 33% in 2013 (Hollingworth et al., 2014). This study did not 
differentiate between DMT initiation, continuation and switching, but the results indicate a rapid 
change of attitude in a country where there are fewer obstacles than in other parts of the world and 
where treatment can be initiated with any approved therapy. 
3.5 Choice of therapy should be an informed, shared decision 
Following a diagnosis of MS, the objective should be to initiate, and continue, treatment with the DMT 
that is most appropriate to the disease course, values, needs, limitations and lifestyle of the individual. 
A 2014 consensus paper by the Multiple Sclerosis Coalition in the USA recommends that the complex 
factors surrounding DMT choice should be discussed collaboratively by the person with MS and their 
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treating MS healthcare professional (Costello et al., 2015). A 2015 position statement by the 
American Academy of Neurology (AAN) concurs that individualized treatment decisions should be 
made by people with MS in conjunction with their treatment team (American Academy of Neurology, 
2015). Guidelines from the ABN, published in 2015, similarly recommend that risks, benefits and 
personal factors are discussed, and that the views of people with MS should be taken into account 
when choosing a DMT (Scolding et al., 2015). 
There is evidence that such dialogue is important to people with MS, and is already happening in 
practice. A 2014 survey of 105 people with MS in the UK showed that 84% wanted to be part of the 
decision-making process (Colhoun et al., 2015). In a 2015 survey of about 5000 people with MS in the 
USA, 43% reported sharing responsibility for treatment decisions with their healthcare professional 
and a further 42% reported that they made the final decision after hearing their doctor’s opinion 
(Cofield et al., 2015). 
Our recommendation is that MS healthcare professionals should have the time to help people with 
MS understand the following so that they can make a fully informed choice of initial DMT: 
 the possible outcomes of their disease with no, inadequate or suboptimal treatment 
 the benefits of early treatment 
 the goal of minimizing disease activity while optimizing safety 
 the potential benefits and risks of DMTs 
 the role they can play in managing their disease by living a ‘brain-healthy’ lifestyle and 
making informed, shared decisions about treatment 
 any limitations in the current understanding of MS and DMTs. 
People with MS need to be fully aware that they have an irreversible disease and that brain atrophy 
and deterioration in cognitive reserve may not manifest as clinical symptoms until later. Informing 
people with MS about their disease has been shown to increase disease-related knowledge, with no 
negative effect (Kopke et al., 2014). Indeed, a recent UK survey found that 59% of people who felt 
adequately informed about treatments for MS were taking a DMT compared with only 27% of those 
who did not feel adequately informed (MS Society, 2013). 
Adherence to prescribed DMTs is associated with fewer relapses that require hospitalization and 
lower medical costs than non-adherence (Bunz et al., 2013) – but adherence to established DMTs is 
incomplete and variable in practice, ranging from 88% to a worryingly low 41% in various studies 
(Menzin et al., 2013). However, when people with MS report that they are well informed about their 
disease and its treatment (de Seze et al., 2012), and have good, open, trust-based relationships with 
healthcare professionals (Costello et al., 2008; Remington et al., 2013), their adherence improves. As 
discussed in Section 2.2.1, MS specialist nurses play a key role in many MS clinical services. As the 
staff members who often have the closest connection to people with MS, they are well placed to 
encourage adherence by establishing trust and rapport, and providing education, emotional support 
and reassurance (Burke et al., 2011). 
The benefits of DMTs most desired by people with MS are symptom control and prevention of 
disability progression (Wilson et al., 2014). Although neurologists and people with MS generally agree 
that the ability to perform work and other day-to-day activities is the most important component of 
health status, neurologists tend to identify physical functioning as being key, while people with MS 
place a strong emphasis on emotional well-being (feeling peaceful, happy and calm) (Kremenchutzky 
and Walt, 2013). This highlights the importance of good dialogue between MS healthcare 
professionals and people with MS. 
When people with MS were offered a theoretical choice of DMTs with no worse than mild side effects, 
the most important factors they identified were route of administration (for example, a pill, an injection 
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or an infusion) and frequency of administration (Utz et al., 2014). However, a 1% risk of a serious side 
effect can reduce patient preference for a particular DMT by fivefold (Wilson et al., 2014). This 
reluctance among people with MS to use DMTs with a greater potential for serious side effects 
highlights the need for a shared, informed exploration of the choices available because the attitudes 
of people with MS towards potential benefits and risks of DMTs may be affected by the options 
offered by neurologists and how these options are presented. 
To summarize, for a person with MS who has the option of receiving a DMT, and has more than one 
choice of DMT, treatment and management decisions rely on how well they understand their disease, 
the extent to which they are risk averse, the experiences of others they know, the pros and cons of 
the available treatments and their neurologist’s willingness to prescribe a newer DMT. 
First-person account (Borreani et al., 2014) 
I only have one appointment a year and don’t feel this is enough. I would like to be informed about 
new research and clinical trials. I am extremely interested in this but have to find this information for 
myself. 
3.6 Recommendations 
Early intervention in MS is vital and needs to involve people with MS proactively in shared decision-
making and the management of their disease. 
 Align prescribing guidelines with the latest accepted diagnostic criteria to give people 
with MS the opportunity to start treatment and receive support promptly, as soon as 
diagnosis is confirmed. 
 Ensure that MS healthcare professionals can take the time to educate people with 
MS about strategies to manage their disease. Emphasize the importance of a ‘brain-
healthy’ lifestyle, the benefits of early treatment with therapies that can modify the disease 
course, the likely consequences of inadequate or suboptimal treatment and the goal of 
minimizing disease activity while optimizing safety. 
 Implement a shared decision-making process that embodies dialogue between people 
with MS and healthcare professionals. A well-informed and proactive collaboration between 
people with MS and their healthcare team is vital to successful management of the disease. 
 Make the full range of disease-modifying therapies available to people with active 
relapsing forms of MS, regardless of their treatment history, to speed up adoption of the 
most appropriate treatment strategy that optimizes effectiveness and safety for each 
individual. 
 Seek regulatory and health technology assessment approvals to implement these 
recommendations. 
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Figure 10. Early intervention with a DMT in MS and CIS is thought to give the best long-term 
prognosis. 
CIS, clinically isolated syndrome; DMT, disease-modifying therapy. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Factor affecting initial 
treatment choice 
Decision-maker(s) Who influences what, and why? 
Licensing National/regional 
regulatory 
authorities 
(e.g. EMA, FDA) 
 The DMT licence dictates the conditions 
under which the DMT can be used 
 Established DMTs are approved as the 
initial treatment for MS in all counties 
where they are available 
 For newer DMTs, there are regional 
differences in the licences. Some are 
available for treatment initiation and 
others can be used only when a person 
with MS has experienced an inadequate 
response to at least one established 
therapy – and these specifics vary by 
country/region 
Prescribing guidelines National/local 
healthcare 
authorities 
 Prescribing guidelines may be more 
restrictive than DMT licences (Wilsdon et 
al., 2013) 
 Prescribing guidelines may not be in line 
with current diagnostic criteria (Multiple 
Sclerosis International Federation, 
2013f) 
Reimbursement National/local policy 
makers, health 
insurance 
companies 
 National and local policy makers (e.g. in 
a particular hospital or practice) and 
health insurance companies can decide 
which DMTs are covered by 
reimbursement (i.e. are paid for) 
 Such decisions effectively govern which 
DMTs are available to people with MS 
Disease course People with MS, 
neurologists, 
regulatory 
authorities 
 Disease severity and speed of 
progression should influence choice of 
initial DMT (Freedman et al., 2013) 
 Some regulatory authorities restrict 
access to DMTs, depending on the 
disease course 
Personal attitudes, 
knowledge and life 
choices 
People with MS, 
neurologists, MS 
specialist nurses 
 All parties should consider the 
importance of several factors, including 
employment, starting or extending a 
family, lifestyle, likely adherence to 
therapy, attitude to risk, aversion to 
injections and existing comorbidities 
 A discussion about the relative 
convenience, effectiveness and risks of 
the DMTs being considered is also 
important 
 
Table 4. Initial treatment choice is affected by DMT licensing, prescribing guidelines and 
reimbursement, as well as by disease course and personal attitudes. 
DMT, disease-modifying therapy; EMA, European Medicines Agency (the European regulatory authority); FDA, 
Food and Drug Administration (the US regulatory authority). 
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Country Data source Date/individuals 
included 
Finding 
Australia Registry (N = 
1113) 
People diagnosed with 
RRMS in 1998–2010a 
18% did not start a DMT during a 
median follow-up period of 2 years 
(Jokubaitis et al., 2013) 
Netherlands Survey (N = 
1572), 89% 
response rate)  
People with MS in 2011 31% had never received a DMT. 
Reasons given included concern 
about side effects, uncertainty about 
the effectiveness of DMTs, disease 
course (mild or progressive) and 
advice received from neurologists 
(Visser and van der Zande, 2011) 
USA Insurance claims 
database (N = 
11061) 
People diagnosed with 
MS in 2001–2007a 
57% did not start a DMT over an 
average follow-up period of 3 years 
(Margolis et al., 2011) 
USA Insurance claims 
database (N = 
7993) 
People diagnosed with 
MS in 2008–2011a 
28% did not start a DMT within 
6 months of diagnosis (Phillips et 
al., 2015) 
 
Table 5. Many people with MS do not start treatment with a DMT. 
aReasons for not starting treatment were not included in the data set. 
DMT, disease-modifying therapy; RRMS, relapsing–remitting multiple sclerosis. 
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Country/regio
n 
Data source Date/individuals 
included 
Finding 
Australia Registry (N = 
771) 
People diagnosed with 
RRMS between 1998 and 
2010 who commenced 
treatment with a DMT 
Almost 99% of those who 
commenced treatment started with 
an established DMT. However, a 
newer DMT became available only 
during the final 24 months of 
the study (Jokubaitis et al., 2013) 
Europe EMA As at September 2015 The EMA has excluded some newer 
DMTs from initial use in most 
people with RRMS (Biogen Idec 
Limited, Revised 22 December 
2014; Novartis Pharma GmbH, 
Revised 24 July 2014) 
USA Survey (N = 75) Neurologists from MS 
treatment centres, 2010 
All recommended initiating a DMT 
for a young adult with mild RRMS; 
90–98% recommended an 
established DMT, depending on 
other risk factors (Tornatore et al., 
2012) 
USA Insurance claims 
database (N = 
6181) 
People with MS who 
commenced treatment 
with a DMT between 
January 2007 and 
September 2009 
93% commenced treatment with an 
established DMT (Bonafede et al., 
2013) 
USA FDA As at September 2015 There is discrepancy between the 
USA and Europe in the licensed 
indications for the use of a particular 
DMT in people with active RRMS 
(Genzyme Corporation, Revised: 14 
November 2014; Genzyme 
Therapeutics Ltd, Revised: 25 
March 2014) 
 
Table 6. Most people with MS who receive a DMT will start with an established treatment. 
DMT, disease-modifying therapy; EMA, European Medicines Agency (the European regulatory authority); FDA, 
Food and Drug Administration (the US regulatory authority); RRMS, relapsing–remitting multiple sclerosis. 
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4. Monitor disease activity and treat to a target 
Key points 
 The practice of monitoring to ensure that disease activity remains below a target level is 
routine in many areas of medicine. 
 In MS, all parameters that predict future relapses and disability progression should be 
included in the definition of disease activity. This definition should evolve as further 
evidence becomes available. 
 Regular clinical and radiological monitoring of disease activity and recording this 
information formally need to become commonplace in managing MS in order to identify 
suboptimal disease control and inform treatment decisions. 
4.1 Monitoring disease activity enables individualized treatment 
There are two primary reasons for monitoring: to evaluate treatment effectiveness and to evaluate 
safety. The monitoring of parameters that indicate disease activity allows the effectiveness of a DMT 
for each individual person with MS to be assessed and enables swift action to be taken in the case of 
treatment failure (Figure 11) (Giovannoni, 2014b) – that is, when disease activity has not been 
minimized in response to treatment (Section 5). The monitoring process should also incorporate 
safety and tolerability parameters, individualized for each DMT, to ensure that people with MS are not 
exposed to unnecessary risk or side effects from their medication (Scolding et al., 2015). 
Monitoring can be either routine or driven by clinical events such as relapses or side effects of 
medication. Parameters that can be monitored may be measured clinically (for example, disability 
progression and relapses), radiologically (using MRI) or in a laboratory (for example, from a blood 
sample), or they may be reported by the person with MS (patient-reported outcomes; for example, 
activity limitations, cognitive status and level of fatigue). Parameters that cannot be measured or 
observed during a clinical examination are known as subclinical parameters. 
The practice of monitoring to ensure that disease activity remains below a target level is routine for 
several conditions that can cause irreversible damage to major organs.  
 In people with diabetes, blood glucose concentrations are routinely monitored, with the aim 
of maintaining them within the normal range to reduce long-term damage to multiple organ 
systems, including the heart, eyes, nerves and kidneys (International Diabetes Federation, 
2011; International Diabetes Federation Clinical Guidelines Task Force, 2012; Handelsman 
et al., 2015).  
 In people with cardiovascular disease (diseases relating to the heart and blood vessels), 
blood pressure and cholesterol levels are monitored and treatment is tailored in order to 
bring them into the normal range. This is done to reduce the risk of cardiovascular events 
that could damage organs such as the heart (from a heart attack, for example) or the brain 
(from a stroke) (Atar et al., 2010). 
 In people with rheumatoid arthritis, treatment based on monthly monitoring has been 
shown to improve physical function and quality of life compared with routine care, at no 
additional cost (routine care here comprised quarterly appointments with specialists, but 
without a formal composite measure of disease activity). Monitoring the number of swollen 
joints, joint tenderness, inflammatory markers in the blood and patient-reported measures 
of disease activity provided the basis for treatment decisions that reduce damage to joints 
(Grigor et al., 2004). Subsequently, an international task force recommended a ‘treat-to-
target’ strategy based on regular monitoring of composite measures of disease activity with 
This is an author’s draft of an accepted article submitted and 
published in Multiple Sclerosis and Related Disorders 
DOI: http://www.sciencedirect.com/science/article/pii/S221103481630102X 
 
 
46 
 
the aim of achieving clinical remission – in this case the absence of significant inflammatory 
disease activity (Smolen et al., 2010). 
Although MS and rheumatoid arthritis cause irreversible damage to different body systems, they have 
several features in common. Both are degenerative, autoimmune, inflammatory conditions that affect 
physical function, and both are treated with DMTs that target the respective inflammatory processes. 
However, in one crucial aspect the management of MS lags behind that of rheumatoid arthritis – in 
MS, the ‘treat-to-target’ approach has not yet been adopted in routine clinical practice. Regular 
monitoring of clinical and subclinical disease activity needs to become central to the 
management of MS (Figure 11) (Giovannoni, 2014b). 
There is also evidence that monitoring can improve adherence to prescribed DMTs (which is 
associated with fewer serious relapses and lower medical costs than non-adherence (Bunz et al., 
2013)) and that data from monitoring can be used to encourage conversations and collaboration 
between people with MS and their healthcare professionals (Willis et al., 2014). Increased 
engagement of people with MS in shared treatment decisions, as recommended in this report, is more 
likely to take place if the routine monitoring of disease activity and safety parameters becomes 
commonplace. 
The remainder of this section presents the evidence for the inclusion of candidate parameters in the 
overall definition of disease activity. 
First-person account 
After receiving a diagnosis of MS in 2005, I began treatment with a DMT. Over the next 5 or 6 years I 
tried three different treatments but continued to have relapses, so I asked my consultant to prescribe 
a different drug for me. I really wanted to see my MRI scans to know what was happening inside my 
brain, but my neurologist was reluctant to show me these. 
I had to be very proactive, push for my case and fight to have my opinion heard. Eventually I was 
switched to a newer treatment. I then realized that this was far more effective than previous drugs had 
been. I stopped experiencing relapses, and I felt less fatigue and that the ‘brain fog’ had lifted, which 
really improved my quality of life. I now visit a different MS neurologist who shares the results of my 
MRI scans with me. I could see for myself that I had no new MRI lesions while taking this new DMT. 
I am happy to make my views clear to neurologists, but not everyone is so comfortable doing this. 
However, I would encourage others with MS to have an active involvement in all the decisions about 
their treatment. Some neurologists are more ‘conservative’ than others and may be reluctant to try 
new treatments. As the person most affected, though, I appreciate being part of the discussion. 
4.2 Clinical and subclinical indicators of disease activity should be monitored 
Historically, the treatment target for MS was to prevent or reduce clinical disease activity – relapses 
and, especially, disability progression (Fox and Rhoades, 2012; Stangel et al., 2015). The need to 
prevent disability progression is underscored by real-world evidence from a large international 
database of people with MS, which indicates that the EDSS score 5 years after the onset of MS 
predicts disability progression, and that once disability has progressed, it worsens more rapidly from 
EDSS score 4.0 onwards than from EDSS score 2.0 onwards (Hughes et al., 2012). 
However, neurological reserve is affected by damage to the CNS even when it does not lead directly 
to disability progression or a relapse (Section 1.2.2); therefore, it makes sense to consider all 
indicators of disease activity, not just the clinical symptoms at the ‘tip of the iceberg’. The remainder of 
this section discusses the clinical and subclinical parameters illustrated in Figure 12 (Giovannoni, 
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2014a), with the greatest focus on the subclinical parameters with the most substantial evidence base 
(MRI lesions and brain atrophy). 
4.2.1 Relapses indicate disease activity and predict disability progression 
Studies consistently show a correlation between relapses in the first few years of the disease and 
later levels of disability (Scalfari et al., 2010; Kieseier, 2014; Scalfari et al., 2014; Stangel et al., 2015). 
The passage of a short time from the first to the second relapse appears to be a particularly strong 
predictor of disability progression (Scalfari et al., 2010; Scalfari et al., 2014). In addition, meta-
analyses and real-world evidence indicate that correlations exist between the effects of DMT on 
relapses and disability progression, and that relapses predict disability progression (Table C.2) 
(Fisniku et al., 2008; Sormani et al., 2009; Sormani et al., 2010; Sormani et al., 2011; Kalincik et al., 
2012; Bermel et al., 2013; Fahrbach et al., 2013; Popescu et al., 2013; Sormani and Bruzzi, 2013; 
Dobson et al., 2014; Uher et al., 2014; Jokubaitis et al., 2015). There is therefore a robust rationale for 
including relapses in the definition of disease activity. 
However, relapses are not the only factor implicated in future disability progression, and there are 
other problems with simply using the recorded ‘relapse rate’. Many relapses go unreported – nearly 
half of people with MS who responded to a recent UK survey indicated that they had failed to report a 
relapse to a healthcare professional, and over one-quarter said that they had not reported their most 
recent relapse (Duddy et al., 2014). In turn, whether or not a relapse is reported can depend on how 
frequently a person with MS sees a neurologist (Freedman et al., 2013). 
4.2.2 MRI lesions indicate disease activity, and predict relapses and disability progression 
Lesions detectable by MRI scans are already used as evidence of disease activity in the diagnosis of 
MS (Section 2.4.2) (Polman et al., 2011) and in clinical trials and as a basis for initiating a DMT in 
many countries (Multiple Sclerosis International Federation, 2013f). Additionally, the EMA recently 
stated that MS may be defined as ‘active’ based on clinical and/or MRI evidence (Genzyme 
Therapeutics Ltd, Revised: 25 March 2014). There is strong evidence for using MRI lesions as a 
predictor of relapses and disability progression from analyses and meta-analyses of data from clinical 
trials and real-world sources involving tens of thousands of people with MS (Table 7) (Sormani et al., 
2009; Sormani et al., 2010; Kalincik et al., 2012; Fahrbach et al., 2013; Popescu et al., 2013; Sormani 
and Bruzzi, 2013; Dobson et al., 2014; Uher et al., 2014). The evidence from each of the studies 
listed in the table is presented in greater detail in Table C.2. 
With the increasing availability of MRI scanners (Multiple Sclerosis International Federation, 2013a), 
the prospect of routinely monitoring brain lesion activity has become viable in many countries. This 
increases the likelihood of detecting disease activity before irreversible damage to brain tissue and 
loss of neurological reserve have occurred. Thus, MRI evidence of subclinical disease activity can 
help to guide treatment decisions in a more timely manner than clinical evidence of disease activity 
(relapses and disease progression) alone. However, despite the major role that MRI plays in the 
diagnosis of MS and the decision to initiate DMT, many people with MS are switched to a different 
DMT only if they experience new clinical symptoms, and not solely on the basis of MRI evidence of 
new lesions (Section 5.2). Moreover, MRI monitoring is not routinely carried out in clinical practice 
everywhere. The ABN, in their 2015 guidelines, suggest incorporating MRI scanning into a routine 
annual review process (Scolding et al., 2015). However, a 2014 survey of 108 UK neurologists with 
an interest in MS revealed that although 59% of respondents used MRI to monitor treatment 
response, only 9% did so routinely (Schmierer et al., 2014). 
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4.2.3 Brain atrophy indicates disease activity and predicts disability progression 
The central theme of this report is that the goal of treating MS should be to preserve brain tissue and 
by doing so optimize lifelong brain health. Brain atrophy occurs as a result of damage that takes place 
via a number of different mechanisms. This implies that brain volume should be monitored in addition 
to active and total numbers of lesions, which represent only one kind of damage. In addition, brain 
volume is a measurable indicator of brain reserve, and rates of brain atrophy higher than those in the 
general population indicate MS disease activity. 
Evidence from studies suggesting that brain atrophy should be included in the definition of disease 
activity as a predictor of clinical symptoms of MS are summarized below. Further details of each study 
are presented in Table C.2 (Kalincik et al., 2012; Popescu et al., 2013; Sormani et al., 2014; Uher et 
al., 2014; Radue et al., 2015). 
 Meta-analyses of clinical trial data show a correlation between the effects of treatment on 
brain atrophy and disability progression (Sormani et al., 2014; Radue et al., 2015). This is 
independent of the correlation between the effects of treatment on MRI lesions and 
disability progression (Sormani et al., 2014) because brain atrophy results from diffuse 
damage and lesions that are difficult to observe, as well as from lesions observable using 
MRI scans (Filippi and Rocca, 2005). 
 Studies in people with CIS receiving a DMT have shown that those with a greater rate of 
brain atrophy are more likely to be diagnosed with MS within 2 years (Kalincik et al., 2012), 
and are more likely to experience a second relapse within 4 years (Uher et al., 2014), than 
those who experience less brain atrophy. 
 Long-term (10 years) disability progression can be predicted by the rate of brain atrophy 
during the first 1–2 years of treatment (Popescu et al., 2013). 
The importance of measuring brain atrophy is already recognized. In a survey of UK neurologists with 
a special interest in MS, over half of the 56 respondents believed that brain atrophy was a relevant 
parameter to measure (Schmierer et al., 2014). However, the MRI technology required to measure 
brain atrophy is not yet widely available in clinical practice. 
4.2.4 Other candidate parameters indicating disease activity are not yet validated 
The evidence base for the other potential markers of disease activity included in Figure 12 (lesions in 
the grey matter of the brain, spinal fluid neurofilament levels and patient-reported outcomes) is 
growing, but is not yet sufficiently strong to support their incorporation into the routine clinical 
monitoring of disease activity in people with MS. In general, we recommend that evidence-based 
treatment targets should evolve as further evidence becomes available. 
The MRI techniques used in current clinical practice can detect lesions in the white matter of the brain 
(which consists mainly of nerve axons that transmit signals between different parts of the brain), but 
MS also affects the grey matter (the part of the brain mainly responsible for cognition and processing 
information). New MRI protocols have been developed to detect lesions in the grey matter (Sethi et 
al., 2012), but the technology and evidence base do not yet exist for adding grey matter lesions to the 
current definition of disease activity. 
Neurofilaments are the protein ‘scaffolding’ of nerve fibres and are released when damage occurs. In 
a recent study in which people with RRMS received one of the newer DMTs for 1 year, reductions in 
the levels of a particular neurofilament in cerebrospinal fluid correlated with lower numbers of 
relapses and fewer new lesions during the same time period (Kuhle et al., 2015). In addition, a recent 
study in people with CIS has shown that levels of the same neurofilament in the blood are high 
compared with those in healthy people, and that higher levels in individuals with CIS were associated 
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with higher disability scores, numbers of lesions and numbers of active lesions (Disanto et al., 2016). 
Furthermore, higher levels of another neurofilament in the blood have been shown to be associated 
with greater numbers of lesions and higher disability scores than lower levels in people with MS 
(Gresle et al., 2014). If results such as these are confirmed by further studies, blood neurofilament 
levels have the potential for adoption as an indicator of subclinical disease activity that is accessible 
even in countries where there are few MRI scanners. 
In 2015, a panel of MS experts proposed the inclusion of measures of cognition, fatigue and 
depression in the definition of disease activity, as these patient-reported outcomes contribute 
substantially towards quality of life in people with MS (Stangel et al., 2015). 
4.3 Regular monitoring provides a strong basis for treatment decisions 
A proactive approach to monitoring, with a clear treatment target, should be adopted as a core 
principle of MS management, and people with MS should be encouraged to request this from their 
clinicians. The proposal of detailed clinical guidelines is beyond the scope of this report, but we 
recommend that any treatment target should be evidence based, and should evolve as further 
evidence becomes available. 
The evidence base presented in this section indicates that MRI evidence of disease activity (or 
inactivity) complements clinical measurements of disease progression and can help to guide 
treatment decisions in a timely manner. Given the strong association between inflammatory lesions 
and subsequent clinical relapses and disability progression, the appearance of new lesions should be 
prospectively and accurately monitored by MRI brain scans performed at predefined intervals. Indeed, 
recent international (Lublin et al., 2014) and Canadian (Traboulsee et al., 2015) consensus papers 
have recommended that disease activity should be assessed at least annually using MRI. 
Ideally, brain volume should also be monitored, because it is a measurable indicator of brain reserve 
and because high rates of brain atrophy in some people with MS are likely to predict poor outcome. 
We acknowledge that routine brain volume monitoring will rely on the incorporation of measurement 
techniques for this parameter into radiological practice, and that the technology required to do this is 
not yet widely available. However, quality monitoring of lesion development (counting new lesions) in 
MRI brain scans is currently feasible and should be routinely carried out in people with MS. 
Recording the results of monitoring in a database or registry, accessed via a clinical management 
tool, can facilitate decisions about lifelong care and treatment for each person with MS because it 
allows MS healthcare professionals to view their full history of disease activity and treatment in one 
place. Systematically monitoring clinical and subclinical indicators of disease activity can help to 
identify treatment failure (suboptimal response to the current DMT). This, in turn, enables prompt 
switching to an alternative DMT to be considered; the evidence that outcomes can be improved by 
such a switch is presented in Section 5. Data from registries can also be analysed in order to 
generate a real-world evidence base that may be used to inform future clinical and regulatory practice 
and demonstrate value to payers (Butzkueven et al., 2006; Flachenecker and Stuke, 2008); this is 
further discussed in Section 6. 
4.4 Recommendations 
Regular clinical and radiological monitoring of disease activity and recording this information formally 
are key to the therapeutic strategy recommended in this report. 
 Include evidence from monitoring via regular clinical evaluation and 
scheduled/unscheduled MRI brain scans in any definitions of disease activity or suboptimal 
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response, in order to assist in the rapid identification of treatment failure and the decision to 
switch treatment. 
 Ensure that MS healthcare professionals can take the time to monitor disease activity 
in people with MS. 
 Agree and implement standardized data collection techniques, protocols and data sets, 
nationally and internationally, to track clinical and subclinical events in routine practice. 
Incorporate these into a clinical management tool to facilitate individualized practice. 
 
 
Figure 11. Monitoring is crucial to identifying treatment failure and enabling timely switching to a 
different DMT (Giovannoni, 2014b). 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Figure 12. Monitoring disability progression and relapses can be supplemented by other measures of 
disease activity (Giovannoni, 2014a). 
MRI, magnetic resonance imaging. 
Reproduced and adapted with permission from Gavin Giovannoni from Biomarkers in MS. EFNS/ENS Joint 
Congress of Neurology, 31 May–3 June 2014, Istanbul, Turkey (Giovannoni, 2014a). © Gavin Giovannoni 2014. 
X, Y and Z represent DMT options. 
DMT, disease-modifying therapy. 
Reproduced and adapted with permission from Gavin Giovannoni from Personalizing treatment choice. 
International MS Physician Summit, 22–23 March 2014, Prague, Czech Republic (Giovannoni, 2014b). © Gavin 
Giovannoni 2014. 
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Correlations exist between the effects of DMTs and: 
 relapses and disability progression (Sormani et al., 2010; Fahrbach et al., 2013) 
 MRI lesions and disability progression (Sormani et al., 2010; Fahrbach et al., 2013) 
 MRI lesions and relapses (Sormani et al., 2009; Sormani and Bruzzi, 2013) 
In people with CIS, the number of new lesions predicts the risk of a second relapse (that is, conversion 
to RRMS by any diagnostic criteria) (Kalincik et al., 2012; Uher et al., 2014) 
The short-term (6–9 months) treatment effect on MRI lesions predicts the medium-term (12–24 
months) treatment effect on relapses (Sormani and Bruzzi, 2013) 
Changes in total lesion load (total volume of lesions visible on MRI) during the first 1–2 years of 
treatment predict long-term (10 years) disability progression (Popescu et al., 2013) 
The initial treatment effect on MRI lesions predicts the long-term (up to 16 years) treatment effect on 
relapses and disability progression (Dobson et al., 2014) 
 
Table 7. MRI lesions predict relapses and disability progression. 
CIS, clinically isolated syndrome; DMT, disease-modifying therapy; MRI, magnetic resonance imaging; RRMS, 
relapsing–remitting multiple sclerosis. 
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5. Act swiftly on the evidence of disease activity 
Key points 
 When the results of monitoring indicate suboptimal disease control, swift action should be 
taken to consider switching the person with MS to a different DMT. 
 The traditional approach towards switching has been to increase the dose or injection 
frequency or to try another DMT with the same mechanism of action (MoA). 
 A number of newer DMTs are now available, with different MoAs, and some of these have 
an evidence base supporting superior efficacy to that of an established DMT. 
 Many people with MS may benefit from switching to one of these newer DMTs, as shown 
by a growing evidence base from clinical trials and real-world studies. 
5.1 Early detection of a suboptimal response to treatment is crucial 
MS is a highly variable disease. No single DMT has yet been shown to be effective in all people with 
MS, and the likelihood that a particular individual will be a responder or a non-responder to any given 
DMT cannot be predicted at present. Consequently, many people with MS may need to try several 
different DMTs before optimal control of disease activity is achieved. Studies have shown that disease 
activity during treatment with a DMT is predictive of a poor prognosis (Rudick and Polman, 2009). 
Prompt detection of disease activity that indicates a suboptimal response to a DMT is therefore very 
important, so that switching to an alternative agent can be considered. 
5.1.1 No consensus exists on the definition of ‘suboptimal response’ 
There is currently no widely agreed definition of a suboptimal response to DMT, nor are there 
universally followed guidelines for managing MS in people who are non-responders. A number of 
authorities have issued guidance, but no single consensus exists (Rudick and Polman, 2009; 
Havrdova et al., 2010; Freedman et al., 2013; Costello et al., 2015; Stangel et al., 2015; Yamout et 
al., 2015). 
A treatment target of ‘no evidence of disease activity’ (NEDA) has been adopted in the 
management of other chronic progressive diseases, such as rheumatoid arthritis (Smolen et al., 
2010), spondyloarthritis (Smolen et al., 2014), lupus (Doria et al., 2015) and cancer (Robinson et al., 
2014b; a). Similarly, NEDA has been proposed as a treatment target in MS by a panel of experts, and 
has been defined as no relapses, no increase in disability and no MRI activity (no new or newly 
enlarged lesions or active lesions) (Havrdova et al., 2009; Havrdova et al., 2010). These experts 
suggest that people with MS should be offered the opportunity to switch to an alternative DMT when 
there is evidence of disease activity according to these criteria. The predictive power of the NEDA 
measure is illustrated by a recent study of 219 people with CIS or RRMS. This showed that if NEDA 
was reached in an individual after 2 years of treatment with a DMT, there was an almost 80% chance 
that their disability would not have progressed 7 years later (by more than 0.5 EDSS points) (Rotstein 
et al., 2015). 
Attaining and maintaining NEDA may not be possible for every person with MS. In the same study, a 
state of NEDA was reached in 27.5% of participants after 2 years and in only 7.9% after 7 years 
(Rotstein et al., 2015). However, most of the participants took established DMTs (as they were 
enrolled in the study before any newer DMTs became available), and the numbers included were too 
low for the relative merits of treatment switching strategies to be evaluated. A similar issue surrounds 
an analysis of four clinical trials of newer DMTs (with an evidence base supporting superior efficacy to 
that of an established DMT), the results of which indicated that NEDA was reached in only 32–39% of 
participants after 2 years of treatment (Rotstein et al., 2015) – there was no option for participants 
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who remained in these trials to switch to a different DMT if they experienced a suboptimal response. 
There is not yet an evidence base that indicates what proportion of people with MS may be expected 
to reach NEDA if all DMTs were available and if MRI indicators of disease activity were routinely 
monitored to enable timely switching.  
Recently, it has been suggested that brain atrophy rate should be included in the definition of NEDA 
(De Stefano et al., 2014b); this would shift the focus of MS treatment to preventing organ damage and 
promoting brain health. In addition, a panel of MS experts has proposed the inclusion of measures of 
cognitive function in the NEDA definition because cognition, fatigue and depression contribute 
substantially towards quality of life in people with MS (Stangel et al., 2015). Furthermore, a measure 
based on the number of new MRI lesions and relapses during the first year of treatment (the ‘modified 
Rio score’) has been shown to predict a poor response to a particular class of established DMT over 
the course of 3 years (Sormani et al., 2013) and 5 years (Romeo et al., 2015). 
5.2 Demonstrable disease activity should raise questions about treatment 
strategy 
Complete freedom from disease activity detectable by MRI is unlikely to be possible for all people with 
MS using current DMTs; however, neurologists should be mindful of the principle and at least aim for 
the lowest level of subclinical disease activity that is not predictive of further suboptimal response. 
The Canadian MS Working Group, in a 2013 paper, recommends managing the treatment of people 
with MS by monitoring three domains: relapses, disability progression and MRI activity (new lesions). 
A change in management would be warranted by high, medium or low levels of concern in one, two or 
three of these domains, respectively (Freedman et al., 2013). The Multiple Sclerosis Coalition in the 
USA, in a 2014 consensus paper, recommends considering switching DMT if there is additional 
clinical or MRI disease activity; this means that a decision to switch treatment could be based on MRI 
evidence alone. The paper also recommends that suboptimal response should be “determined by the 
individual and his or her treating physician” (Costello et al., 2015). The ABN, in its 2015 guidelines, 
notes that “new MRI lesions are a more sensitive index of inflammatory disease activity than clinical 
relapses.” (Scolding et al., 2015) 
However, in practice, switching tends to be based on clinical evidence alone. Regulatory authorities 
guide the circumstances under which a named DMT can be initiated, but they do not define 
suboptimal response and seldom provide guidance on when to switch from one DMT to another. 
Currently, some neurologists will not switch a person with MS to a different DMT without clinical 
evidence of disease activity (relapses or disability progression), even when clear MRI evidence of 
disease activity is available (Tornatore et al., 2012; Hanson et al., 2014). In a survey of MS specialist 
nurses in the UK, conducted in January 2014, 72% of respondents reported that they would wait for 
two or more relapses before referring a person with MS for a review of their DMT. In addition, most 
neurologists in the USA recommend a minimum treatment duration of 6–12 months before switching 
to another DMT for reasons of inadequate disease control (Tornatore et al., 2012), as treatment can 
take some time to take effect.  
The development of a clinical guideline is outside the scope of this report, but we recommend that 
treatment targets and definitions of ‘disease activity’ and ‘suboptimal response’ should be evidence 
based, should evolve as further evidence becomes available and should aim to maximize lifelong 
brain health. 
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5.3 What happens in current clinical practice? 
5.3.1 Switching among established therapies is common 
The majority of people with relapsing forms of MS start treatment with an established DMT that was 
approved during the 1990s (Section 3.4). Within 2 years of starting an established DMT, about one-
third to two-thirds of people with MS are classified as ‘non-responders’ or ‘suboptimal responders’, as 
defined by a variety of different clinical measures involving relapses and/or disability progression 
(Romeo et al., 2013; Prosperini et al., 2014). This proportion could be higher if the description of 
disease activity included MRI measures (Barkhof et al., 1992). 
Among the established DMTs, there are only two MoAs. Owing to the limited options available, a 
traditional strategy for treatment switching was to increase the dose or injection frequency, or to try 
another DMT with the same MoA. In a US study involving 6181 people with MS who initiated 
treatment with a DMT in 2007–2009, 79% of those who switched from an initial established DMT did 
so to another established DMT; the rest switched to a newer DMT. Of those who switched for a 
second time, about two-thirds received yet another established DMT (Bonafede et al., 2013). This 
approach could indicate a reluctance to prescribe more recently approved DMTs until options 
involving established DMTs have been exhausted. Now that several newer DMTs with a range of 
MoAs are available, however, a 2014 consensus paper by the Multiple Sclerosis Coalition 
recommends that non-responders consider switching to a different DMT regimen, for example to one 
with a different MoA (Costello et al., 2015). 
5.3.2 Attitudes towards newer therapies vary 
The decision to prescribe a newer DMT might be influenced by prescribing guidelines, drug 
reimbursement policies, insurance company rules at the local, regional or national level, patient 
choice and concerns regarding potential side effects (Table 4 in Section 3.3.2). Furthermore, some 
neurologists may be wary of the need to change routine clinical practice in order to meet the 
monitoring requirements of some newer DMTs. Neurologists are familiar with managing the side 
effects of established treatments; however, newer DMTs have different safety profiles from those of 
established DMTs and some require a greater degree of monitoring (Damal et al., 2013; Rommer et 
al., 2014). Therefore, people with MS and their treating healthcare professionals need to balance the 
potentially higher efficacy levels of some newer DMTs against their individual risk profiles (Damal et 
al., 2013; Rommer et al., 2014). 
The varying attitudes towards innovation among professionals in specialist fields, such as neurology, 
should not be underestimated; they can result in geographical differences in the approach to disease 
management or the speed of adoption of newer treatments. This sociological phenomenon is known 
as the ‘diffusion of innovation’ (Rogers, 2003) and, alongside factors such as a lack of up-to-date 
information, it may account for differences in overall practice patterns. 
The proportion of people receiving treatment for MS who were given a newer DMT varied widely 
between countries in 2013 (Figure 13) (Multiple Sclerosis International Federation, 2013i; h; Wilsdon 
et al., 2013; Hollingworth et al., 2014; World Bank, 2015b) and even within countries. For example, 
data from Australia show that newer DMT use rose from 8% to 33% of total DMT use in 2011 and 
2013, respectively. When the figures for newer DMT use in 2013 are broken down according to states 
and territories within the country, they range from 17% to 40% of total DMT use (Hollingworth et al., 
2014). 
Combination therapy (i.e. using more than one drug at the same time) has been successfully 
employed to treat certain types of cancer (Wu et al., 2015), a complex disease in which drugs with 
different MoAs can have an additive effect. Such an approach is also being investigated for people 
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with MS whose disease is inadequately controlled, but clinical experience is currently limited 
(Freedman et al., 2013). 
5.3.3 Discontinuation and treatment gaps are common 
Gaps in the treatment of people with active MS are thought to be equivalent to, or worse than, periods 
of non-adherence, and hence treatment gaps will have a negative impact on the disease course. 
When switching treatment, 30% of people with MS have gaps in their therapy exceeding 30 days, and 
almost 20% have gaps in excess of 60 days (Margolis et al., 2011). Some regulatory authorities 
recommend treatment gaps when switching between certain DMTs to avoid the risk of unwanted 
effects on the immune system that might increase the likelihood of serious infections (Biogen Idec 
Limited, Revised 22 December 2014; Novartis Pharma GmbH, Revised 24 July 2014). Real-world 
evidence indicates that such gaps can increase the risk of a relapse; this evidence could be used as a 
basis for updating recommendations about the maximum length of treatment gaps (Jokubaitis et al., 
2014). 
5.4 Choice of therapy should be an evidence-based decision 
Delaying treatment switching, or excluding the use of newer DMTs, may be detrimental to establishing 
rapid control of the disease before further relapses or disability progression occur. Indeed, a recent 
position paper by the AAN recommends that people with MS should be able to access all DMTs 
“when they have the potential to provide clinical benefit” and that any treatment sequences imposed 
by payers or insurance carriers should be driven by evidence-based data and not DMT costs 
(American Academy of Neurology, 2015). 
There is increasing evidence that people with MS whose disease is inadequately controlled by an 
established DMT will benefit from receiving an appropriate newer DMT. Several studies have shown 
that people with MS who switch from an established DMT to a newer DMT (with an evidence base 
supporting superior efficacy to that of an established DMT) are more likely to be free from relapses 
(Prosperini et al., 2012; Bergvall et al., 2014; He et al., 2015; Spelman et al., 2015), disability 
progression (Prosperini et al., 2012; He et al., 2015; Spelman et al., 2015) and new MRI activity 
(Prosperini et al., 2012) – and can even experience improvements in their disability status (He et al., 
2015) – compared with switching to another established DMT. A number of other studies have 
demonstrated that improvements in disability (Kallweit et al., 2012; Svenningsson et al., 2013; 
Butzkueven et al., 2014a; Kalincik et al., 2015a), quality of life measures (Khatri et al., 2014), fatigue 
(Svenningsson et al., 2013) and cognition (Svenningsson et al., 2013) are also possible when people 
with MS receive a newer DMT (with an evidence base supporting superior efficacy to that of an 
established DMT; Table D.1) (!!! INVALID CITATION !!! (Khatri et al., 2011; Kallweit et al., 2012; 
Prosperini et al., 2012; Svenningsson et al., 2013; Baldi et al., 2014; Bergvall et al., 2014; Butzkueven 
et al., 2014a; Khatri et al., 2014; Meng et al., 2014; He et al., 2015; Kalincik et al., 2015a; Spelman et 
al., 2015)). As adequate control of disease activity will not always be achieved in all people with MS 
taking any one DMT, regular monitoring should be the cornerstone of any treatment strategy 
(Section 4). 
The favourable results obtained in the studies that compared treatment switching indicate that 
neurologists should consider evidence-based approaches to using newer DMTs in people with 
relapsing forms of MS and suboptimally controlled disease activity. As with treatment initiation 
(Section 3.6), the full range of DMTs should be considered when switches are made, to enable 
people with MS and their treating healthcare professionals to make fully informed, shared decisions. 
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5.5 Recommendations 
Rapid switching to another DMT if monitoring reveals a suboptimal response will maximize the 
chance of achieving the best possible outcome for every person with MS who would be at risk of 
inflammatory disease activity if they were not receiving treatment. 
 Ensure that MS healthcare professionals can take the time to educate people with 
MS about strategies to manage their disease. Emphasize the importance of a ‘brain-
healthy’ lifestyle, the benefits of early treatment with therapies that can modify the disease 
course, the likely consequences of inadequate or suboptimal treatment and the goal of 
minimizing disease activity while optimizing safety. 
 Implement a shared decision-making process that embodies dialogue between people 
with MS and healthcare professionals. A well-informed and proactive collaboration between 
people with MS and their healthcare team is vital to successful management of the disease. 
 Make the full range of disease-modifying therapies available to people with active 
relapsing forms of MS, regardless of their treatment history, to speed up adoption of the 
most appropriate treatment strategy that optimizes effectiveness and safety for each 
individual. 
 Maintain treatment with a disease-modifying therapy for as long as a person with MS 
would be at risk of inflammatory disease activity if they were not receiving treatment; in the 
case of a suboptimal response, make a prompt decision about whether or not to 
switch therapy. 
 Seek regulatory and health technology assessment approvals to implement these 
recommendations. 
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Figure 13. The proportion of people with all forms of MS receiving a newer DMT in 2013 varied 
considerably between countries. 
aAll newer DMTs available at the time that these studies were conducted have an evidence base supporting 
superior efficacy to that of an established DMT. 
The data were generated from DMT sales figures as described in the original sources (Wilsdon et al., 2013; 
Hollingworth et al., 2014), and therefore potentially include people with all forms of MS (relapsing or progressive), 
and do not differentiate between treatment initiation and treatment switching. All DMTs for Australia: calculation 
based on sales figures (Hollingworth et al., 2014), population (World Bank, 2015b) and number of people with MS 
(Multiple Sclerosis International Federation, 2013h).  
DMT, disease-modifying therapy. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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6. Take a comprehensive economic approach to evaluating 
treatment cost-effectiveness 
Key points 
 As a person with MS becomes more disabled, costs outside the healthcare system 
markedly increase until they comprise about two-thirds of all costs. 
 The treatment strategy outlined in this report, of early intervention, regular monitoring and 
timely switching of therapy to maximize lifelong brain health, has the potential to reduce 
disability progression and therefore to avoid some of these long-term costs. 
 However, most health technology assessment (HTA) bodies and reimbursement agencies 
consider only the costs borne by healthcare and social services. This leads to suboptimal 
decisions, where DMTs that have the potential to provide an economic benefit to society as 
a whole may not be considered cost effective. 
 The global prices of DMTs – as for other pharmaceutical products – are generally set 
based on the conditions in high-income countries, and other countries may have difficulties 
in granting access to these therapies. 
 Current financing models focus on the prices of individual DMTs; however, this effectively 
incentivizes the rationing of individual drugs instead of focusing on finding the optimal 
therapy for each person with MS. Alternative financing models should, therefore, 
be investigated. 
 For people with MS in low-income countries, access to DMTs can be improved by 
developing financial support programmes and less-expensive DMTs. 
 Recording the results of monitoring in databases or registries will generate real-world 
evidence of the effectiveness and safety of individual DMTs and therapeutic strategies. 
This can be used to inform future clinical and regulatory practice. 
6.1 All benefits and costs should be included in economic evaluations 
6.1.1 Costs outside the healthcare system increase as disability progresses 
As a person with MS becomes more disabled, costs outside the healthcare system, such as informal 
care and production losses due to incapacity to work, markedly increase until they comprise about 
two-thirds of all costs (Figure 8 in Section 1.4) (Kobelt et al., 2006b). Diagnosing and treating MS 
early needs to be coupled with a management strategy based on monitoring, and with increased 
payer flexibility to switch among all DMTs at the first sign of disease activity; this will help to preserve 
brain tissue, maximize lifelong brain health and reduce the likelihood of relapses and disability 
progression (Sections 2–5). Although the immediate direct costs of DMTs and the demands on 
healthcare resources (such as MRI) are likely to increase with this approach (Russo et al., 2004), the 
high costs occurring in the later stages of MS will be reduced if unnecessary disability progression 
can be avoided. 
6.1.2 National health technology assessments evaluate what to fund from the 
public budget 
When a treatment has been approved by the relevant regulatory authority, a national HTA body will 
generally assess its value – the health benefits in relation to costs – to decide whether it will be 
funded from the public budget. A formal economic evaluation of health outcomes and costs is 
used to support this decision in most countries (International society for pharmacoeconomics and 
outcomes research (ISPOR), 2015). 
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Health outcomes are commonly measured using quality-adjusted life-years (QALYs). These 
measure the effect of a treatment on length and quality of life and can be compared across diseases 
(Weinstein et al., 2009). A treatment that reduces the likelihood of a person dying early, or improves 
health-related quality of life, will have a positive impact on QALYs. Some economic evaluations also 
consider the impact that informal caregiving has on the health of family members. This is highly 
applicable to MS – indeed, the results of a recent survey indicate that caregivers’ health-related 
quality of life deteriorates as the person with the disease becomes more disabled (Acaster et al., 
2013). 
6.1.3 Costs of informal care and incapacity to work are not always considered 
It is widely accepted that economic evaluations of health outcomes should include all potential health 
benefits to all parties. It is logical, therefore, that economic evaluations should also consider the 
potential costs to all parties (Jonsson, 2009); in other words, they should take a societal 
perspective. However, most HTA bodies and reimbursement agencies have adopted a payer 
perspective, where only the costs borne by healthcare and social services are considered. The costs 
to wider society, such as informal care and incapacity to work, are often considered only in a 
secondary analysis – or not at all. 
6.1.4 Direct costs commonly accrue in one part of society and benefits in another 
Adopting a payer perspective (narrow cost model) leads to suboptimal decisions, with the result that 
treatments with the potential to provide an economic benefit to society (other than savings to 
healthcare services) may not be considered to be cost effective (Jonsson, 2009). It is quite normal for 
direct costs to accrue in one part of society and benefits in another. As the health-related benefits of 
treatment are enjoyed by people with the disease and their families, it is only fair to factor in also the 
burden of informal care and indirect costs that would otherwise be borne by these parties to a large 
extent. In the case of MS in particular – a chronic, progressive disease that starts at a young age – 
taking a societal viewpoint is crucial when evaluating the potential for the long-term health benefits of 
early treatment with a DMT to outweigh the costs. Our recommendation is that economic evaluations 
should be carried out from a societal perspective; in other words, that they should consider health 
benefits and costs to all parties. 
6.2 Access to disease-modifying therapies should be improved 
6.2.1 Access to DMTs varies widely 
Access to DMTs depends not only on clinical effectiveness and the decisions of regulatory authorities 
(Table 4) but also on affordability. In the USA, prices have increased five to seven times more rapidly 
than prescription drug inflation, and currently no DMTs cost less than US$50000 (€37500) per year 
for an individual person with MS. These US costs are two to three times higher than those in 
Australia, Canada or the UK (Hartung et al., 2015). As global prices for DMTs are generally set based 
on the conditions in high-income countries, healthcare providers in some other countries may have 
difficulties in granting wide access to them. Compared with a more wealthy nation, healthcare 
expenditure in a low-income country will not only be less in absolute terms but will also constitute a 
lower proportion of total expenditure as health care competes with other basic necessities. As a 
consequence, reimbursement of the costs of DMTs in different countries varies from no funding at all, 
particularly for newer therapies, to full reimbursement (Figure 14) (Multiple Sclerosis International 
Federation, 2013e; d; c; b; World Health Organization, 2015). 
Policy makers could encourage the pharmaceutical industry to expand the scope of existing financial 
support programmes, so as to improve access where it is currently limited. Offering discounts in this 
way, however, could create the problem of parallel trade (the import of DMTs purchased elsewhere at 
This is an author’s draft of an accepted article submitted and 
published in Multiple Sclerosis and Related Disorders 
DOI: http://www.sciencedirect.com/science/article/pii/S221103481630102X 
 
 
61 
 
a lower price), which would need to be controlled – a topic that is beyond the scope of this report. The 
development and use of less-expensive DMTs (for example, generic versions) could also help to 
make these drugs more accessible to people with MS in low-income countries. 
6.2.2 Access to newer DMTs varies widely 
Even in high-income and upper-middle-income countries where the costs of newer DMTs are fully 
reimbursed, access to these therapies varies widely. Given that newer DMTs tend to be more 
expensive than established DMTs (Hartung et al., 2015), much of this difference appears related to 
affordability. A correlation exists between the proportion of people with MS who are on treatment and 
receiving a newer DMT and the per capita spending on health care (Figure 15) (Wilsdon et al., 2013; 
Hollingworth et al., 2014; World Health Organization, 2015). 
Sometimes, additional administrative restrictions are put in place to limit the number of people with 
MS who can receive treatment and, thus, limit the budget that can be spent on DMTs. In some 
Eastern European countries, affordability has historically led to waiting lists or limits on the length of 
time for which a person with MS can be prescribed a DMT (Wilsdon et al., 2013). 
HTA bodies have restricted reimbursement to a narrower group of people with MS than that specified 
by the EMA in some high-income countries. For example, the EMA indicates that a particular newer 
DMT can be used in (a) people with RRMS whose disease has failed to respond to at least 1 year of 
treatment with an established DMT, or (b) those with rapidly evolving, severe RRMS (Biogen Idec 
Limited, Revised 22 December 2014). In the Netherlands, however, reimbursement is restricted to 
people in group (a), while in England reimbursement is restricted to those in group (b). In Italy, the 
restrictions for group (a) regarding recent relapses are tighter than the EMA indication, while in 
Belgium the DMT costs will only be reimbursed for people below a certain disability level on the EDSS 
(Wilsdon et al., 2013). 
6.3 Alternative financing models should continue to be investigated 
Our recommendation is that the full range of DMTs should be available to people with active relapsing 
forms of MS, regardless of their disease history, so that they and their treating healthcare 
professionals can make shared, informed decisions about treatment. Established DMTs feature 
prominently in budgets set aside for specialty drugs that are used in all disease areas (Express 
Scripts, 2015). In order to provide greater access to newer DMTs, investigations into alternative 
financing models should be continued. 
Current payment systems tend to focus on the cost per pack/vial of medicine, which was an important 
factor in the 1990s, when fewer DMTs were available than today. In this context, the advent of 
biosimilar drugs (generic versions of biological drugs that can be marketed once the original patent 
has expired) and the approval of further newer DMTs is likely to drive an overall focus on reducing the 
cost per pack/vial of DMT. Improved outcomes for people with MS, however, are seldom the 
consequence of treatment with just one DMT. Rather, they result from a therapeutic strategy that aims 
to find the most appropriate DMT for each individual by switching treatment if there is evidence of 
disease activity. It is not logical from a societal perspective, therefore, for payment systems to focus 
on the costs of individual DMTs rather than the optimal treatment for each person with MS. 
One possible solution is a capitation, or ‘payment per patient per month’, scheme in which a fixed 
payment is made in return for a negotiated range of services (NHS England, 2014). Such payments 
may be combined with additional payments that are conditional on meeting selected quality or 
outcome standards. This could help to incentivize keeping each person with MS as well as possible, 
and it may promote an integrated approach to care, with optimized procedures for diagnosis, 
monitoring and treatment switching. 
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6.4 Real-world evidence should drive regulatory and funding decisions 
The therapeutic strategy of early treatment, monitoring and switching, with the full range of DMTs 
available, will change the economic picture of MS and has the potential to reduce the long-term costs 
of the disease significantly. Regulatory authorities and payers, however, make initial decisions about 
DMTs based on their efficacy and safety in short-term clinical trials – an environment in which it is not 
possible to switch to a different DMT if disease activity is inadequately controlled. Consideration of 
real-world evidence from registries and databases of the long-term effectiveness and safety of DMTs 
and therapeutic strategies will help regulatory authorities, HTA bodies and payers to ensure that these 
decisions do not become out of date or rigid, denying people with MS the flexibility to benefit from the 
most recent evidence. 
The registries that currently exist, however, have been set up independently of one another, for 
different reasons, and they cover different kinds of patient populations. As a result, the parameters 
collected, and the data collection techniques and protocols that are followed, are often not 
standardized (Flachenecker et al., 2014). In this context, two international data sets that have 
overcome some of these hurdles are worthy of note: 
 MSBase is an online registry that individual MS clinics can choose to sign up to 
(Butzkueven et al., 2006). As of July 2015, it contains over 35000 patient records from 199 
clinics in 69 counties (MSBase, 2015), and it has led to the publication of a number of 
papers, including several presenting real-world evidence of the effectiveness of DMTs 
(Section 5.4) (Spelman et al., 2013; Butzkueven et al., 2014b; Jokubaitis et al., 2014; He et 
al., 2015; Kalincik et al., 2015a; Kalincik et al., 2015b; Spelman et al., 2015). 
 The European Register for Multiple Sclerosis (EUReMS) aims to unite existing national MS 
registries around a core data set (Pugliatti et al., 2012). To date, data have been provided 
from 13 registries, although only three participating national registries contain the 
parameters necessary for inclusion in a study assessing the effectiveness and accessibility 
of DMTs (European Multiple Sclerosis Platform, 2014). 
The routine monitoring of people with MS with an agreed minimum data set has not yet been widely 
adopted, although we earlier recommended standardizing and recording the results of treatment and 
routine monitoring in the context of a clinical management tool to facilitate individualized practice 
(Section 4.3). Additionally, we recommend incorporating such results into national and international 
MS registries and databases in order to generate real-world evidence of the long-term effectiveness 
and safety of individual DMTs. This would also enable the effectiveness of overarching therapeutic 
strategies to be evaluated, for example the predictive power of NEDA (by any definition covered by 
the data set) on clinical outcomes or the effect of variations in practice patterns on disease activity 
and health outcomes for people with MS. For this to be possible, we further recommend that the 
curators of databases and registries should ensure accessibility of data to those performing HTAs and 
economic evaluations. 
6.5 Recommendations 
The therapeutic strategy of early treatment, monitoring and switching, with the full range of DMTs 
available, will change the economic picture of MS and has the potential to reduce the long-term costs 
of the disease significantly. 
 Carry out economic evaluations of therapies and other healthcare interventions from 
a societal perspective, considering the health benefits and costs to all parties, to improve 
assessments of true cost-effectiveness. 
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 Encourage the continuing investigation, development and use of cost-effective 
therapeutic strategies, of approaches that reduce the costs of managing MS and of 
alternative financing models, to improve access to treatment. 
 Agree and implement standardized data collection techniques, protocols and data sets, 
nationally and internationally, to track clinical and subclinical events in routine practice. 
Incorporate these into national and international MS registries and databases to generate 
real-world evidence of the long-term effectiveness and safety of therapeutic strategies; 
such evidence can be used by regulatory bodies and payers, and will enable differences in 
practice patterns to be assessed and addressed. 
 Ensure that access to multiple sclerosis registries and databases is available for those 
carrying out health technology assessments and economic evaluations. 
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Figure 14. The costs of DMTs, especially newer DMTs, are more likely to be reimbursed in higher-
income countries than in lower-income countries (Multiple Sclerosis International Federation, 2013e; 
d; c; b; World Health Organization, 2015).  
aBy the government and/or by health insurance. 
 
DMT, disease-modifying therapy; high-income country, gross national income per capita ≥ $12746 in 2013; 
upper-middle-income country, gross national income per capita ≥ $4125 and < $12746 in 2013; lower-middle-
income country, gross national income per capita ≥ $1045 and < $4125 in 2013; low-income country, gross 
national income per capita ≤ $1045 in 2013 (World Bank, 2015a). 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Figure 15. The prescription of newer DMTs (as a proportion of total DMTs) (Wilsdon et al., 2013; 
Hollingworth et al., 2014) is highest in countries with high per capita healthcare expenditure (World 
Health Organization, 2015). 
All countries shown offer full or partial government reimbursement for the cost of established therapies and for at 
least one newer DMT.  
DMT, disease-modifying therapy; PPP, purchasing power parity. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Appendix A. Recommendations 
Multiple sclerosis has a profound personal, social and economic impact. Better outcomes for people 
with MS and those who care for them can be achieved if organizations implement the following three 
sets of recommendations. 
1. Minimize delays in the diagnosis of MS and in the time to treatment initiation as these can 
result in irreversible disability progression. 
 
 Educate the general public to take prompt action if early 
symptoms of MS develop, by visiting a healthcare professional. 
Awareness campaigns that highlight the typical initial symptoms, the 
negative impact of delaying treatment and the personal and societal 
costs of the disease would support this. 
National bodies 
Patient groups 
 
 Educate family and primary care physicians about the 
importance of promptly referring people with suspected MS to a 
neurologist, and ultimately to a specialist clinic, to speed up 
diagnosis and treatment initiation. 
National bodies 
Professional bodies 
Healthcare providers 
 Recommend that general neurologists refer people suspected of 
having the disease to specialist MS neurologists. 
National bodies 
Professional bodies 
Healthcare providers 
 Improve access to specialist care for MS: make diagnostic and 
monitoring procedures more widely accessible, increase the numbers 
of healthcare professionals who specialize in the management of 
MS, and ensure that these specialists provide prompt diagnostic and 
support services for people with suspected MS and those who have 
been newly diagnosed with the disease. 
National bodies 
Healthcare providers 
Reimbursement 
agencies 
 Adopt the latest accepted diagnostic criteria, in order to diagnose 
MS as early as possible. 
National and 
international bodies 
Healthcare providers 
 Align prescribing guidelines with the latest accepted diagnostic 
criteria to give people with MS the opportunity to start treatment and 
receive support promptly, as soon as diagnosis is confirmed. 
National bodies 
Healthcare providers 
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2. Set goals for treatment and ongoing management that aim for the best possible outcome 
for every person with MS. 
 
 Ensure that MS healthcare professionals can take the time to 
educate people with MS about strategies to manage their 
disease. Emphasize the importance of a ‘brain-healthy’ lifestyle, the 
benefits of early treatment with therapies that can modify the disease 
course, the likely consequences of inadequate or suboptimal 
treatment and the goal of minimizing disease activity while optimizing 
safety. 
National bodies 
Professional bodies 
Healthcare providers 
 Implement a shared decision-making process that embodies 
dialogue between people with MS and healthcare professionals. A 
well-informed and proactive collaboration between people with MS 
and their healthcare team is vital to successful management of the 
disease. 
National bodies 
Professional bodies 
Healthcare providers 
 Make the full range of disease-modifying therapies available to 
people with active relapsing forms of MS, regardless of their 
treatment history, to speed up adoption of the most appropriate 
treatment strategy that optimizes effectiveness and safety for each 
individual. 
Regulatory authorities 
Healthcare providers 
Health technology 
assessors 
Reimbursement 
agencies 
 Include evidence from monitoring via regular clinical evaluation 
and scheduled/unscheduled MRI brain scans in any definitions 
of disease activity or suboptimal response, in order to assist in 
the rapid identification of treatment failure and the decision to 
switch treatment. 
Healthcare providers 
Regulatory authorities 
 Ensure that MS healthcare professionals can take the time to 
monitor disease activity in people with MS. 
National bodies 
Healthcare providers 
 Agree and implement standardized data collection techniques, 
protocols and data sets, nationally and internationally, to track 
clinical and subclinical events in routine practice. Incorporate these 
into a clinical management tool to facilitate individualized practice. 
National and 
international bodies 
Healthcare providers 
Curators of registries 
and databases 
 Maintain treatment with a disease-modifying therapy for as long 
as a person with MS would be at risk of inflammatory disease activity 
if they were not receiving treatment; in the case of a suboptimal 
response, make a prompt decision about whether or not to 
switch therapy. 
Healthcare providers 
Reimbursement 
agencies 
 Seek regulatory and health technology assessment approvals to 
implement these recommendations. 
Pharmaceutical 
companies 
Professional bodies 
Patient groups 
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Any other 
stakeholders 
3. Consult the most robust evidence base possible, and generate further evidence, in order to 
make good decisions about therapeutic and management strategies for MS. 
 
 Carry out economic evaluations of therapies and other 
healthcare interventions from a societal perspective, considering 
the health benefits and costs to all parties, to improve assessments 
of true cost-effectiveness. 
Health technology 
assessors 
Reimbursement 
agencies 
Patient groups 
 Encourage the continuing investigation, development and use 
of cost-effective therapeutic strategies, of approaches that reduce 
the costs of managing MS and of alternative financing models, to 
improve access to treatment. 
Regulatory authorities 
Healthcare providers 
Health technology 
assessors 
Reimbursement 
agencies 
 Agree and implement standardized data collection techniques, 
protocols and data sets, nationally and internationally, to track 
clinical and subclinical events in routine practice. Incorporate these 
into national and international MS registries and databases to 
generate real-world evidence of the long-term effectiveness and 
safety of therapeutic strategies; such evidence can be used by 
regulatory bodies and payers, and will enable differences in practice 
patterns to be assessed and addressed. 
National and 
international bodies 
Healthcare providers 
Curators of registries 
and databases 
 Ensure that access to multiple sclerosis registries and 
databases is available for those carrying out health technology 
assessments and economic evaluations. 
National and 
international bodies 
Healthcare providers 
Curators of registries 
and databases 
 
National bodies may include government departments or private organizations, depending on the country in 
question. 
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Figure A.1. We recommend a therapeutic strategy that aims to preserve central nervous system 
tissue and maximize lifelong neurological reserve (an important component of brain health) by 
reducing disease activity. 
Reproduced with permission from Oxford PharmaGenesis Ltd. © 2015 Oxford PharmaGenesis Ltd. 
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Appendix B. Evidence supports the benefit of early treatment  
Results from clinical trials and real-world studies support early intervention with a DMT in CIS and RRMS. 
Table B.1. In people with a diagnosis of CIS, treatment with a DMT increases the time to a second relapse and improves MRI outcomes in randomized 
controlled trials. 
 
Length of time taking 
DMT or placeboa 
Results Study details 
3 years IM IFN-β1a vs placebo 
 Reduced risk of second relapseb  (Jacobs et al., 2000; O'Connor, 
2003) 
 Fewer new lesions (Jacobs et al., 2000) 
 Fewer active lesions at 18 months (Jacobs et al., 2000) 
 Lower total volume of lesions (Jacobs et al., 2000) 
Study: CHAMPS 
Groups: IM IFN-β1a (n = 193); placebo (n = 190) 
(Jacobs et al., 2000) 
‘High risk’ subgroupc: SC IFN-β1a (n = 51); placebo 
(n = 40) (O'Connor, 2003) 
2 years SC IFN-β1a vs placebo 
 Reduced risk of second relapse (Comi et al., 2001) 
 Increased time to second relapse (Comi et al., 2001) 
 Lower relapse rate (Comi et al., 2001) 
 Fewer new lesions (Comi et al., 2001) 
 Lower total volume of lesions (Comi et al., 2001) 
 Reduced rate of brain atrophy (Filippi et al., 2004) 
Study: ETOMS  
Groups: IM IFN-β1a (n = 154); placebo (n = 154) 
(Comi et al., 2001) 
Subgroup for which baseline brain volume 
measurements were available: SC IFN-β1a (n = 
131); placebo (n = 132) (Filippi et al., 2004) 
 
2 years SC IFN-β-1b vs placebo (Kappos et al., 2006a) 
 Increased time to second relapse 
Groups: SC IFN-β-1b (n = 292); placebo (n = 176) 
3 years GA vs placebo (Comi et al., 2009) 
 Reduced risk of second relapse 
 Increased time to second relapse 
Study: PreCISe 
Groups: GA (n = 243); placebo (n = 238) 
2 years SC IFN-β-1b vs placebo (Comi et al., 2012) Study: RELFEX 
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 Reduced risk of second relapse 
Groups: SC IFN-β-1b 3 times a week (n = 171); SC 
IFN-β-1b once per week (n = 175); placebo (n = 
171) 
2 years Teriflunomide vs placebo (Miller et al., 2014) 
 Reduced risk of second relapse 
 Reduced risk of new lesions 
Study: TOPIC 
Groups: Teriflunomide, 14 mg (n = 216), 7 mg (n = 
205); placebo, n = 197 
 
Participants in all studies had been diagnosed with CIS and had clinically silent MRI lesions. All positive outcomes shown were statistically significant. 
aOr until a second relapse. 
bBoth in the main trial and in a post hoc analysis of a 'high risk' subgroupc 
cParticipants with ≥ 9 T2 lesions or ≥ 1 gadolinium-enhancing lesion at baseline. 
CHAMPS, Controlled High-risk subjects Avonex Multiple sclerosis Prevention Study; CIS, clinically isolated syndrome; DMT, disease-modifying therapy; ETOMS, Early 
Treatment of Multiple Sclerosis; GA, glatiramer acetate; IFN-β, interferon beta; IM, intramuscular; MRI, magnetic resonance imaging; PreCISe, Evaluate early glatiramer 
acetate treatment in delaying conversion to clinically definite multiple sclerosis of subjects Presenting with Clinically Isolated Syndrome; REFLEX, REbif FLEXible Dosing in 
Early Multiple Sclerosis; SC, subcutaneous; TOPIC, Oral teriflunomide versus placebo in Patients with first clinical symptom of multiple sclerosis.  
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Table B.2. In people with a diagnosis of CIS, starting treatment early in the disease course is associated with better long-term outcomes than delaying 
treatment in randomized controlled trials with subsequent extension studies. 
Length of time taking 
DMT or placeboa 
Subsequent length of 
time taking DMT 
Results Study details 
3 years 2 years Early DMT vs later DMT (Comi et al., 2013) 
 Reduced risk of second relapse 
 Increased time to second relapse 
 Less brain atrophy 
 Fewer new lesions per year 
 Lower total lesion volume 
Study: PreCISe open-label extension 
DMT: GA 
Groups: early DMT (n =198); later DMT (n = 
211) 
3 years 10 years Early DMT vs later DMT (Kinkel et al., 2012) 
 Reduced risk of second relapse 
 Lower relapse rate between years 
5 and 10 of extension 
 No effect on disability progression, 
new lesions or proportion of people 
developing progressive MS 
Study: CHAMPIONS (open-label extension of 
CHAMPS) 
DMT: IM IFN-β1a 
Groups: early DMT (n = 81); later DMT (n = 74) 
2 years 9 years Early DMT vs later DMT (Edan et al., 2015) 
 Increased time to second relapse 
 Lower relapse rate 
 No effect on disability progression 
Study: BENEFIT11 
DMT: SC IFN-β1b 
Groups: early DMT(n = 178); later DMT (n = 
106) (Edan et al., 2014) 
 
Participants in all studies had been diagnosed with CIS and had clinically silent MRI lesions. All positive outcomes shown were statistically significant. 
aOr until a second relapse. 
BENEFIT11, Betaferon/ Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment 11-year follow-up; CHAMPS, Controlled High-risk subjects Avonex Multiple 
sclerosis Prevention Study; CHAMPIONS Controlled High-risk Avonex Multiple sclerosis Prevention study In Ongoing Neurological Surveillance; CIS, clinically isolated 
syndrome; DMT, disease-modifying therapy; GA, glatiramer acetate; IFN-β, interferon beta; IM, intramuscular; PreCISe, Evaluate early glatiramer acetate treatment in delaying 
conversion to clinically definite multiple sclerosis of subjects Presenting with Clinically Isolated Syndrome; SC, subcutaneous 
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Table B.3 In people with a diagnosis of RRMS, starting treatment early in the disease course is associated with better long-term outcomes than delaying 
treatment. 
Study type Length of time 
taking DMT or 
placebo 
Subsequent 
part of study: 
length of time 
and treatment 
Results Study details 
RCT, then 
extension 
2 years 2 years, DMT 
(blinded) 
Early DMT vs later DMT (Prisms Study Group 
and University of British Columbia MS/MRI 
Analysis Group, 2001) 
 Longer time to sustained disability 
progression 
 Fewer new lesions 
 Lower total brain lesion volume 
Study: PRISMS-4  
DMT: SC IFN-β1a 
Groups: early DMT 22 µg (n = 167), 44 µg (n 
= 167); later DMT 22 µg (n = 97), 44 µg (n = 
95) 
RCT, then 
open-label 
extension 
2 years 4 years, DMT Early DMT vs later DMT (Kappos et al., 2015) 
 Less disability progression 
 Lower relapse rate 
 Less brain atrophy 
Study: FREEDOMS extension 
DMT: Fingolimod  
Groupsa: early DMT, 0.5 mg (n = 330), 1.25 
mg (n = 287); later DMT, 0.5 mg (n = 154), 
1.25 mg (n = 145) 
RCT, then 
extension 
2 years 4 years, DMTb 
then 1–2 years, 
treatment at 
discretion of 
physician 
Early DMT vs later DMT (Kappos et al., 
2006b) 
 Lower risk of disease progression 
 Lower relapse rate 
 Lower total brain lesion volume 
 No effect on brain atrophy 
Study: PRISMS long-term follow-up  
DMT: SC IFN-β1a 
Groups: early DMT 22 µg (n = 123), 44 µg (n 
= 136); later DMT 22 µg (n = 66), 44 µg (n = 
63) 
RCT, then 
open-label 
extension 
9 months 9 months DMT 
then 3.8–4.9 
years treatment 
at discretion of 
physician 
Early DMT vs later DMT (Rovaris et al., 2007) 
 Lower proportion of people 
requiring walking aids 
 No effect on total lesion volume, 
normalized brain volume or brain 
atrophy rate 
Study: European/Canadian GA study long-
term follow up 
DMT: GA 
Groups: early DMT (GA since study initiation) 
(n = 73), later DMT (n = 69) 
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RCT, then 
open-label 
extension 
2.5 years 5.5 years, DMT Early DMT vs later DMT (Johnson et al., 
2005) 
 Higher proportion of people with 
stable or improved EDSS score 
(i.e. lower risk of disability 
progression) 
 No effect on relapse rate 
Study: Copolymer I Multiple Sclerosis Study 
open label extension 
DMT: GA 
Groupsc: early DMT (n = 72), later DMT (n = 
70) 
RCT, then 
treatment at 
discretion of 
physician 
2 years 15 years, 
treatment at 
discretion of 
physician 
Early DMT vs later treatment (Bermel et al., 
2010) 
 No statistically significant effect on 
disability progression 
Study: ASSURANCE (follow-up of MSCRG) 
DMT: IM IFN-β1a 
Groups: early DMT (n = 69); later treatment 
(n = 67) 
RCT, then 
treatment at 
discretion of 
physician 
5 years 16 years, 
treatment at 
discretion of 
physician 
Early DMT vs later treatment 
 Better survival rates: risk of death 
47%/46% lower (early 250µg / 
early 50µg DMT respectively 
versus later treatment) (Goodin et 
al., 2012b); 78% (54/69) of deaths 
in delayed treatment group 
adjudicated to be from MS-related 
causes (Goodin et al., 2012a) 
 No effect on disability progression, 
relapse rate or MRI parameters 
(Ebers et al., 2010) 
Study: IFN-β Multiple Sclerosis Study 21 year 
long-term follow-up 
DMT: SC IFN-β-1b 
Groups: 
 Survival known: early DMT 50 µg (n 
= 109), 250 µg (n = 104); later 
treatment (n = 88) (Goodin et al., 
2012b) 
 Case report form available: early 
DMT 50 µg (n = 85), 250 µg (n = 96); 
later treatment (n = 79) (Ebers et al., 
2010) 
Post hoc 
analysis of 
two RCTs 
1 year 
(TRANSFORM
S) / 2 years 
(FREEDOMS) 
– Time between onset of symptoms and 
treatment: < 3 years vs ≥ 3 years (Agius et 
al., 2014) 
 Greater reduction in relapse rate 
vs placebo and vs IM IFN-β1a 
Studies: TRANSFORMS and FREEDOMS 
DMT: Fingolimod or IM IFN-β1a 
Subgroups: 
Time from symptoms to treatment < 3 years 
fingolimod (n = 132 in TRANSFORMS, n = 
113 in FREEDOMS); IM IFN-β1a (n = 140 
TRANSFORMS); placebo (n = 104 in 
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 Fewer new/newly enlarged 
lesions/year vs placebo and vs IM 
IFN-β1a 
 Fewer active lesions vs placebo 
FREEDOMS).  
Time from symptoms to treatment  ≥ 3 years: 
fingolimod (n = 297 in TRANSFORMS, n = 
312 in FREEDOMS), IM IFN-β1a (n = 291 in 
TRANSFORMS), placebo (n = 314 in 
FREEDOMS) 
Real-world 
evidence 
from registry 
Treatment 
initiation 
occurred within 
1–5 years of 
onset of MS 
– Early treatment (within 1 year of onset) vs 
later treatment (Trojano et al., 2009) 
 Reduced risk of disability 
progression (a 1-point increase in 
EDSS score) 
 Reduced risk of reaching EDSS 
score ≥ 4.0 
Study: A cohort of RRMS patients (N = 2570) 
was prospectively followed for up to 7 years 
DMT: IFN-β preparation  
Real-world 
evidence 
from registry 
7 years (DMT or 
no DMT) 
– DMT vs no DMT (Trojano et al., 2007) 
 Reduced risk of transition to SPMS 
 Reduced risk of reaching EDSS 
score ≥ 4.0 
 Increased time to reaching EDSS 
score ≥ 4.0 
 Reduced risk of reaching EDSS 
score ≥ 6.0  
 Increased time to reaching EDSS 
score ≥ 6.0 
Study: A cohort of RRMS patients (N = 1504) 
was prospectively followed for up to 7 years 
DMT: IFN-β preparation 
Groups: DMT (n = 1103); no DMT (n = 401) 
 
Participants in all studies had been diagnosed with RRMS. All positive outcomes shown were statistically significant. 
aIntention to treat population. 
b2 year blinded extension, followed by a further 2 year extension (blinded or open label as chosen by each individual patient). 
cn for 8 year data 
ASSURANCE,  ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs; DMT, disease-modifying therapy; EDSS, Kurtzke Expanded Disability Status Scale; 
FREEDOMS, FTY720 Research Evaluating Effects of Daily Oral Therapy in MS; GA, glatiramer acetate; IFN-β, interferon beta; IM, intramuscular; MRI, magnetic resonance 
imaging; MSCRG, Multiple Sclerosis Collaborative Research Group; PRISMS, Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis; 
RCT, randomized controlled trial; RRMS, relapsing–remitting multiple sclerosis; SC, subcutaneous; SPMS, secondary progressive multiple sclerosis; TRANSFORMS, Efficacy 
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and safety of fingolimod in patients with relapsing-remitting multiple sclerosis with optional extension phase. 
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Appendix C. Relapses, lesions and brain atrophy indicate disease activity 
Table C.1 Relapses predict disability progression; MRI lesions predict relapses and disability progression. 
Study type Outcomes Results Study details 
Meta-analysis Disability progression 
Relapse rate 
New lesions 
 Treatment effects on relapses and 
disability progression are correlated 
(R2 = 0.75) 
 Treatment effects on new lesions and 
disability progression are correlated 
(R2 = 0.64)  
Included all clinical trials in CIS, RRMS and 
SPMS published between 1 January 1993 
and 3 June 2013 (N = 18809) (Fahrbach et 
al., 2013) 
Meta-analysis Relapse rate 
Active lesions 
 Treatment effects on active lesions and 
relapses are correlated (R2 = 0.81) 
Included all clinical trials in RRMS published 
before 1 September 2008 (23 trials, N = 
6591) (Sormani et al., 2009) 
Meta-analysis Relapse rate 
New or active lesions 
 Treatment effect on MRI lesions (after 6–9 
months) predicts treatment effect on 
relapses (after 12–24 months) 
 Concurrent treatment effects on MRI 
lesions and relapses are correlated 
(R2 = 0.71)  
Included all clinical trials in RRMS published 
between 1 September 2008 and 31 October 
2012 (31 trials, N = 18901) (Sormani and 
Bruzzi, 2013) 
Meta-analysis Disability progression 
Relapse rate 
MRI lesions 
 Treatment effects on relapses and 
disability progression are correlated 
(R2 = 0.71) 
 Treatment effects on MRI lesions and 
disability progression are correlated 
(R2 = 0.57)  
Included all published clinical trials in RRMS 
(19 trials, N = 10009) (Sormani et al., 2010) 
Meta-analysis Disability progression 
Relapses 
Active lesions 
New lesions 
 Initial poor response to IFN-β, as 
measured by active and new lesions, 
predicts clinical outcomes (relapses and 
disability progression) up to 16 years after 
treatment initiation 
Included clinical trials of IFN-β preparations 
in CIS and RRMS published between 1 
January 2000 and 21 May 2013 (11 trials, N 
= 2171) (Dobson et al., 2014) 
Retrospective analysis Disability progression 
(after 10 years) 
 Changes in brain atrophy and lesion load 
both predict EDSS disability progression 
MRI scans conducted in people with MS who 
also had 10-year follow-up disability data 
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Total volume of lesions 
(change over 1–2 years) 
Brain atrophy 
(change over 1–2 years) 
10 years after the initial MRI scan in a 
‘relapse onset’ subgroup containing people 
with CIS, RRMS and SPMS 
(N = 166) (Popescu et al., 2013) 
RCT followed by 
treatment at discretion 
of physician 
Disability progression 
Relapses 
Active lesions 
New lesions 
 Number of relapses, active lesions and 
new lesions during initial 2 years of 
observation predict disability progression 
15 years later 
2-year RCT (MSCRG study) in which people 
with RRMS received IM IFN-β1a, followed by 
15 years of treatment at discretion of 
physician (ASSURANCE study) (N = 69) 
(Bermel et al., 2013)  
RWE Disability progression 
Relapses 
New lesions 
Brain atrophy 
 Number of new lesions and brain atrophy 
predict a second relapse (that is, 
conversion to RRMS under any diagnostic 
criteria) within 4 years 
Real-world study of people with CIS treated 
with IM IFN-β1a for 4 years (N = 210) (Uher 
et al., 2014) 
RWE Disability progression 
New lesions 
Brain atrophy 
 Number of lesions at baseline and rate of 
brain atrophy during first 6 months of 
observation predict conversion to RRMS 
Real-world study of people with CIS treated 
with IM IFN-β1a for 2 years (N = 220) 
(Kalincik et al., 2012) 
RWE Disability progression 
Relapses 
 Time to confirmed disability progression is 
associated with relapse rate 
Real-world study of people with CIS (N = 
1989) (Jokubaitis et al., 2015) 
RWE Disability progression 
MRI lesions 
 Total volume of lesions and rate of change 
of lesion volume (especially during the first 
5 years) both moderately predict disability 
progression 20 years later 
Real-world study of people with CIS (N = 
107) (Fisniku et al., 2008) 
All results shown were statistically significant. 
R2 is a measure of how much of the variability in one item (e.g. disability progression) is shared with another item (e.g. new lesions). For example, R2 = 0.64 means that 64% of 
the variation in one item is explained by variation in the other. 
CIS, clinically isolated syndrome; DMT, disease-modifying therapy; EDSS, Kurtzke Expanded Disability Status Scale; IFN-β, interferon beta; IM, intramuscular; MRI, magnetic 
resonance imaging; MSCRG, Multiple Sclerosis Collaborative Research Group; RCT, randomized controlled trial; RRMS, relapsing–remitting multiple sclerosis; RWE, real-
world evidence; SPMS, secondary progressive multiple sclerosis. 
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Table C.2 Brain atrophy predicts relapses and disability progression. 
Study type Outcomes Results Study details 
Meta-analysis Disability progression 
New/enlarging lesions 
Brain atrophy 
 Treatment effects on brain atrophy 
and disability progression are 
correlated (R2 = 0.48) 
 Treatment effects on new/enlarging 
MRI lesions and disability 
progression are correlated 
(R2 = 0.61) 
 The correlation with disability 
progression is greater when both of 
these MRI markers are combined 
(R2 = 0.75)  
Included all published clinical trials in RRMS of 
at least 2 years in duration published before 
December 2012 (13 trials, N > 13500) 
(Sormani et al., 2014) 
Post hoc analysis Disability progression 
Brain atrophy 
 Rate of brain atrophy is associated 
with disability progression 
Analysis of three published clinical trials of 
fingolimod in RRMS (N = 3635) (Radue et al., 
2015) 
Retrospective analysis Disability progression (after 10 
years) 
Total volume of lesions visible on 
MRI (change over first 1–2 years) 
Brain atrophy (change over first 
1–2 years) 
 Brain atrophy and lesion volume 
both predict EDSS disability 
progression 10 years after the initial 
MRI scan in a ‘relapse onset’ 
subgroup containing people with 
CIS, RRMS and SPMS 
MRI scans conducted in people with MS who 
also had 10-year follow-up disability data (N = 
166) (Popescu et al., 2013) 
RWE Disability progression 
Relapses 
New lesions 
Brain atrophy 
 Number of new lesions and brain 
atrophy predict a second relapse 
(that is, conversion to RRMS under 
any diagnostic criteria) within 4 years 
Included people with CIS treated with IM IFN-
β1a for 4 years (N = 210) (Uher et al., 2014) 
RWE Disability progression 
New lesions 
Brain atrophy 
 Lesion volume at baseline and rate 
of brain atrophy during first 6 months 
of observation predict conversion to 
RRMS 
Included people with CIS treated with IM IFN-
β1a for 2 years (N = 220) (Kalincik et al., 2012) 
 
All results shown were statistically significant. 
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R2 is a measure of how much of the variability in one item (e.g. disability progression) is shared with another item (e.g. new lesions). For example, R2 = 0.64 means that 64% of 
the variation in one item is explained by variation in the other. 
CIS, clinically isolated syndrome; DMT, disease-modifying therapy; EDSS, Kurtzke Expanded Disability Status Scale; IFN-β, interferon beta; MRI, magnetic resonance 
imaging; MS, multiple sclerosis; RRMS, relapsing–remitting multiple sclerosis; RWE, real-world evidence; SPMS, secondary progressive multiple sclerosis. 
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Appendix D. Growing evidence supports the use of appropriate newer therapies 
Table D.1 There is increasing evidence that people with MS whose disease is inadequately controlled by an established DMT will benefit from receiving an 
appropriate newer DMT. 
Study type Results Study details 
RCT and open label 
extension  
Early fingolimod vs later fingolimod 
 Lower relapse rate (Khatri et al., 2011) 
 Fewer new lesions (Khatri et al., 2011) 
 Fewer people with active lesions (Khatri et al., 2011) 
 No effect on disability progression (Khatri et al., 
2011) 
 Longer time to next relapsea (Meng et al., 2014) 
RCT (TRANSFORMS): 1 year of treatment 
with fingolimod or IM IFN-β1a 
Extension: 1 year of treatment with fingolimod 
(N = 1027; continuous fingolimod: 0.5 mg 
[n=356], 1.25 mg (n=330); switch from IM IFN-
β1a to fingolimod: 0.5 mg [n = 167], 1.25 mg [n 
= 174]) 
RWE, propensity 
matched groups 
Switch to natalizumab vs switch between established DMTs 
(GA or IFN-β preparations) (Spelman et al., 2015) 
 Reduced disability progression over 2 years 
 Reduced relapse rate in year 1 
 Reduced risk of first on-treatment relapse in year 1 
 Reduced risk of disability progression in first 3 
months 
2 years of treatment with natalizumab, GA or 
an IFN-β preparation following an on-treatment 
relapse in the 12 months before switching 
while taking GA or an IFN-β preparation (N = 
1838; switch to natalizumab, n = 869 [from 
TOP]; switch to GA/IFN-β, n = 869 [from 
MSBase]) 
RWE Switch to natalizumab vs switch between established DMTs 
(GA or IFN-β preparations) (Prosperini et al., 2012) 
 Greater proportion of people with no relapses, no 
disability progression and no new MRI lesions after 
2 years 
 No significant differences after 1 year 
2 years of treatment with natalizumab, GA or 
an IFN-β preparation following treatment 
failureb with GA or an IFN-β preparation (N = 
285; switch to natalizumab, n = 106c; switch 
among established DMTs, n = 161c) 
RWE, propensity 
matched groups 
Natalizumab or fingolimod vs baseline (before switching from 
an established DMT) (Kalincik et al., 2015a) 
 Reduced relapse rate 
 Greater improvements in disability (i.e. improved 
function) 
12 months (on average) of treatment with 
natalizumab or fingolimod following an on-
treatment relapse and/or disability progression 
while taking GA or an IFN-β preparation 
(N = 578; natalizumab, n = 407; fingolimod, n = 
171) 
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RWE, propensity 
matched groups 
Switch to fingolimod vs switch between established DMTs (He 
et al., 2015) 
 Reduced relapse rate 
 Reduced risk of a further relapse 
 Reduced risk of disability progression 
 Increased probability of improvements in disability 
(i.e. improved function) 
13 months (on average) of treatment with 
fingolimod, GA or an IFN-β preparation 
following an on-treatment relapse and/or 
disability progression while taking GA or an 
IFN-β preparation (N =  527; n = 148 
fingolimod, n = 379 GA or an IFN-β 
preparation) 
RWE, propensity 
matched groups 
Switch to fingolimod vs switch to GA (Bergvall et al., 2014) 
 Reduced relapse rate 
 Reduced probability of a further relapse 
Treatment with fingolimod or GA following 
switching from an IFN-β preparation (N = 264; 
fingolimod, n = 132; GA, n = 132) 
Open label study 
(TOP) 
Natalizumab vs baseline (before starting treatment with 
natalizumab) (Butzkueven et al., 2014a) 
 No worsening in disability on average (unchanged 
mean EDSS scores) 
 Annual relapse rate lower at years 1–5 than at  
baseline 
Up to 5 years of treatment with natalizumab 
(N = 4821) 
RWE Natalizumab vs baseline (before starting treatment with 
natalizumab) (Kallweit et al., 2012) 
 Improvements in disability on average (i.e. improved 
function) during first year of treatment 
 No worsening in disability between baseline and 
year 3 (n = 23) 
 Annual relapse rate fell between baseline and year 3 
(n = 23) 
Up to 3 years of treatment with natalizumab 
(N = 64) 
Open label study 
(TYNERGY) 
Natalizumab vs baseline (before starting treatment with 
natalizumab) (Svenningsson et al., 2013) 
 Improvements in disability (i.e. improved function), 
walking speed, quality of life, cognition, fatigue, 
depression and sleepiness compared with baseline 
1 year of treatment with natalizumab (N = 195) 
Open label study 
(TRUST) 
Natalizumab vs baseline (before starting treatment with 
natalizumab) (Khatri et al., 2014) 
6 months of treatment with natalizumab in 
people with MS and disabling bladder 
dysfunction (N = 30) 
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 Improvements in incontinence-related quality of life 
after 6 months compared with baseline 
 
All results shown were statistically significant. 
aAnalysis carried out post hoc; switch from IM IFN-β1a to fingolimod (observed) compared with model of continued IM IFN-β1a (estimated). 
bTreatment failure was defined as the occurrence of ≥ 2 relapses or 1 relapse with residual disability. 
cNumber of patients included in analysis. 
DMT, disease-modifying therapy; EDSS, Kurtzke Expanded Disability Status Scale; GA, glatiramer acetate; IFN-β, interferon beta; MRI, magnetic resonance imaging; 
RCT, randomized controlled trial; RWE, real-world evidence; TOP, Tysabri (natalizumab) Observational Program; TRUST, EvaluaTion of Bladder Function in Relapsing-
Remitting Multiple Sclerosis Patients Treated with Natalizumab; TYNERGY, Effects of Tysabri (natalizumab) over 12 months on MS-related fatigue in participants with RRMS.
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